Anemia of cancer in a spontaneously breast cancer developing mouse model by Fàbregas Bregolat, Núria
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Anemia of cancer in a spontaneously breast cancer developing mouse model
Fàbregas Bregolat, Núria
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-176287
Dissertation
Published Version
Originally published at:
Fàbregas Bregolat, Núria. Anemia of cancer in a spontaneously breast cancer developing mouse model.
2019, University of Zurich, Vetsuisse Faculty.
  
Institute of Veterinary Physiology 
of the Vetsuisse Faculty University of Zurich 
 
 
 
 
Director: Prof. Dr. med. vet. Max Gassmann 
 
 
 
 
Work under the academic supervision of 
Dr. Markus Thiersch 
 
 
 
 
 
Anemia of cancer in a spontaneously breast cancer developing mouse model  
 
 
 
 
 
Inaugural Thesis 
 
 
 
to obtain the title of Doctor from the 
Vetsuisse Faculty University of Zurich 
 
 
 
submitted by 
 
 
 
Núria Fàbregas Bregolat  
 
Veterinarian 
of Barcelona, Spain 
 
 
Approved at the request of: 
 
Prof. Dr. med vet. Max Gassmann, supervisor 
 Prof. Dr. Ben Wielockx, co-supervisor  
 
2019 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
3 
 
Table of contents 
1. Summary........................................................................................................................... 5 
2. Zusammenfassung ............................................................................................................ 6 
3. Introduction ...................................................................................................................... 7 
3.1 Anemia of cancer .......................................................................................................... 7 
3.2 Pathophysiology of AC ................................................................................................. 8 
3.3. Therapeutic approach of AC ...................................................................................... 14 
3.4 Mouse models of AC .................................................................................................. 17 
3.5 Rational and objectives ............................................................................................... 18 
4. Material and methods .................................................................................................... 19 
4.1 Animal Experiments ................................................................................................... 19 
4.2 Analyzing mRNA expression by real time PCR .......................................................... 22 
4.3 Analyzing plasma Epo concentration .......................................................................... 24 
4.4 Hematology and Clinical biochemistry ....................................................................... 24 
4.5 Histology .................................................................................................................... 24 
4.6 Analyzing plasmatic interleukin-6 concentration......................................................... 25 
4.7 Iron parameters in plasma ........................................................................................... 26 
4.8 Analyzing ferritin concentration in plasma .................................................................. 27 
4.9. Non-heme iron measurement in tissue........................................................................ 27 
4.10 Bone marrow smears ................................................................................................ 29 
4.11 Flow cytometry experiments ..................................................................................... 29 
4.12 Statistics ................................................................................................................... 33 
5. Results ............................................................................................................................. 34 
5.1 Trp53floxWapCre mice develop breast cancer associated with Epo-resistant anemia .... 34 
5.2 Trp53floxWapCre mice develop AC at advanced stages of tumorigenesis .................... 35 
5.3 Trp53floxWapCre mice develop a marked inflammatory response during tumor 
progression ....................................................................................................................... 39 
5.4 Reduced iron availability in tumor-bearing Trp53floxWapCre mice ............................. 42 
5.5 Altered iron metabolism in tumor-bearing Trp53floxWapCre mice ............................... 46 
   
 
4 
5.6 Tumors of Trp53floxWapCre mice do not cause anemia when transplanted into 
immunocompromised Foxn1nu mice ................................................................................. 48 
5.7 Single intravenous injection of ferric carboxymaltose (Ferinject®) does not mitigate 
anemia in tumor-bearing Trp53floxWapCre mice ............................................................... 49 
5.8 Iron treatment acutely stimulates erythropoiesis in spleen but not in bone marrow of 
Trp53floxWapCre mice ...................................................................................................... 52 
5.9 Impaired bone marrow erythropoiesis in tumor-bearing Trp53floxWapCre mice cannot 
be compensated by activated stress erythropoiesis in the spleen ........................................ 54 
5.10 Hematopoiesis in spleen and bone marrow of Trp53floxWapCre mice is differently 
regulated .......................................................................................................................... 60 
6. Discussion ....................................................................................................................... 62 
6.1 Trp53floxWapCre mice develop Epo-resistant anemia. ................................................. 62 
6.2 Anemic tumor-bearing Trp53floxWapCre mice show severe inflammation and immune 
response ........................................................................................................................... 64 
6.3 Hypoferremia in anemic tumor-bearing Trp53floxWapCre ........................................... 65 
6.4 Iron supplementation does not mitigate AC in Trp53floxWapCre mice ......................... 67 
6.5 Impaired medullary hematopoiesis in Trp53floxWapCre mice is partially compensated 
by induced stress erythropoiesis in the spleen ................................................................... 68 
6.6 Secretion of cytokines by the tumor might stimulate the myelopoiesis in bone marrow 
and prevent erythropoiesis in Trp53floxWapCre mice ........................................................ 71 
7. Conclusion and outlook .................................................................................................. 74 
8. References ....................................................................................................................... 75 
9. Supplemental .................................................................................................................. 84 
10. Acknowledgement............................................................................................................. 
11. Curriculum Vitae ............................................................................................................. 
 
 
 
 
   
 
5 
1. Summary  
Anemia of cancer (AC) has a high prevalence and capital clinical impact in cancer patients 
but is underdiagnosed and undertreated, due to the lack of effective and safe therapies. For 
a better treatment, it is essential to understand this pathological condition and to test 
potential strategies in preclinical models. However, few animal models to study AC have 
been established so far and none of them represents a spontaneously tumor-developing 
model. We characterized anemia in a spontaneously mammary tumor forming 
Trp53floxWapCre mouse model to evaluate its usability as a model for AC. We observed 
that tumor-bearing mice develop inhibition of medullar erythropoiesis and prominent stress 
hematopoiesis in spleen, insensitivity to erythropoietin, a marked activation of the immune 
system and hypoferremia. Hypoferremia was treated by different protocols of single 
intravenous iron injections (Ferinject®), but iron supplementation was not sufficient to 
prevent AC, indicating that iron was not the limiting factor in our model. Impaired 
medullary erythropoiesis was accompanied by a marked induction of the myelopoiesis in 
bone marrow and spleen which might be a cancer-associated immunosuppressive strategy 
caused by several factors secreted by the tumor. Our model reflects a large variety of AC-
related pathological changes that may complicate studies and drug tests but that might also 
reflect the human patient situation much closer than simplified cancer cell transplantation 
models. 
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2. Zusammenfassung  
 
Anämie kommt in Krebspatienten häufig vor und beeinträchtigt die Lebensqualität und 
Prognose. Da sichere und effektive Behandlungsoptionen fehlen, ist die Krebsanämie 
unterdiagnostiziert und unterbehandelt. Für bessere Behandlungen müssen Pathologie und 
Behandlungsoptionen besser untersucht werden. Es gibt jedoch nur vereinfachte Tiermodelle, 
aber keines mit spontaner Tumorentwicklung. Wir haben die Pathologie von anämischen 
Trp53floxWapCre Mäusen mit Brustkarzinom charakterisiert, um deren Verwendung als 
präklinisches Model zu testen.  Trp53floxWapCre Mäuse entwickeln Anämie durch Inhibition 
der Erythropoese im Knochenmark, begleitet durch eine Stress-Erythropoese in der Milz. Das 
Immunsystem wird deutlich aktiviert und es kommt zu einer Hypoferrämie, welche wir durch 
Eisensupplementation (Ferinject®) korrigieren wollten. Jedoch gelang es uns nicht die Anämie 
zu unterbinden, d.h. Eisenverfügbarkeit stellt nicht der limitierende Faktor in unserem Modell 
das. Die beeinträchtigte Erythropoese im Knochenmark haben wir auf eine starke Myelopoese 
zurückgeführt.  
Unser Model spiegelt die Variabilität der Pathologie von Krebsanämien wider, und somit 
eventuell auch die klinische Situation von Patienten besser, als es vereinfachte Modelle mit 
Tumorzellimplantation könnten. Insbesondere die Unempfindlichkeit gegenüber Epo macht 
dieses Model einzigartig, um diesen Typ der Krebsanämie sowie Behandlungsoptionen der 
Zytokin-abhängigen Suppression der Erythropoese zu untersuchen. 
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3. Introduction 
 
3.1 Anemia of cancer 
Anemia in cancer patients is very frequent and exhibits a profound impact on the quality of life 
and on disease prognosis of cancer patients. 39% of them are anemic before starting any 
treatment1 and it rises up to 90% in patients going under chemotherapy.2 The incidence is 
influenced by the type of cancer,3,4 sex and age of the patient5,6 as well as on the stage of the 
disease,7,3,4 being more severe in patients at advanced stages. The main consequence of anemia 
is the reduced capacity of oxygen transport within the organism and therefore affecting the 
function and metabolism of all organs and tissues. The most common symptoms are fatigue, 
weakness and reduced cognitive and physical capacity,8 which result mainly from the response 
to hypoxia in the circulatory and renal systems9 as well as in the tissues.  
Anemia is one of the main reasons for cancer-related fatigue.10 This fatigue can negatively 
influence the patient’s tolerance and motivation to undergo antineoplastic treatment, thus not 
allowing patients to receive adequate and complete treatments and potentially impairing the 
therapeutic response.11  Moreover, anemia is an independent risk factor for survival regardless 
of tumor type7 and it seems to impair the tumor responsiveness to chemo- and 
radiotherapy.12,3,13,14,15,16,17 Furthermore, anemia and the subsequent reduced oxygen transport 
might increase tumor hypoxia and thus, tumor malignancy, favoring tumor progression and 
metastasis formation through different mechanisms. These mechanisms include tissue acidosis, 
production of reactive oxidative species (ROS), immunodepression and alterations in tumor 
cells apoptosis.18 Therefore, anemia in cancer is not only important for its role in deteriorating 
the quality of life and reducing the treatment options of the patients, but also because it increases 
tumor progression and spreading.  
Despite its vast importance and major presence among cancer patients, this condition is still 
nowadays left untreated due to its complex pathogenesis and the potential risks of the current 
therapeutic approaches19 such as infections after blood transfusion20 or promoting tumor growth 
after Epo treatment.21  
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3.2 Pathophysiology of AC 
In oncologic patients, anemia can be caused by multiple factors like the direct invasion of the 
bone marrow by the neoplastic cells, nutritional deficiencies, hemorrhage, hemolysis, kidney 
disease, liver insufficiencies, or the direct myelosuppressive effect of radio- or chemotherapy 
among others.22 However, it is important to note that the term Anemia of Cancer (AC) 
specifically refers to a type of anemia, that is caused by chronic inflammation associated with 
advanced stages of cancer and the synthesis of proinflammatory cytokines by immune and 
cancer cells.23  
The main mechanisms by which inflammation and released  proinflammatory cytokines can 
cause anemia are: alterations in iron metabolism that lead to an iron restricted erythropoiesis; 
shortened erythrocyte life-span and increased erythrocyte destruction; direct suppression of 
erythropoiesis in bone marrow; and inhibition of the production of erythropoietin (Epo) in 
kidney24 (Fig. 1). In some patients the immune response to the tumor leads to the formation of 
antibodies that destroy the red blood cells (RBC) (autoimmune hemolytic anemia) or suppress 
the erythrocyte production (pure red-cell aplasia). In other AC types, the damage of the vascular 
endothelium by tumor emboli or activation of the coagulation by the tumor can physically injure 
erythrocytes and accelerate their destruction (microangiopathic hemolytic anemia).25 In some 
cases, the tumor evokes an immune response characterized by massive phagocytosis of marrow 
cells.26 
Figure 1 
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Fig. 1: Main pathogenic mechanisms of AC. Tumor cells produce and release cytokines and/or activate the immune system. 
The latter secreting more cytokines and factors causing anemia. These factors and cytokines can reduce iron availability for 
erythropoiesis, increase the turnover of the circulating erythrocytes or inhibit erythropoiesis either directly or by suppressing 
Epo production in the kidney. 
 
Alterations in iron metabolism  
Iron is involved in many vital functions of the body, including erythropoiesis, where it is 
necessary for the synthesis of hemoglobin. Conversely, excess of iron in the organism can be 
harmful due to its oxidizing potential and its capacity to generate reactive oxygen species 
(ROS), which damages tissues and organs.27,28 For this reason, iron metabolism is tightly 
regulated under physiologic conditions in order to maintain systemic and cellular iron 
homeostasis.29  
The iron balance in the body can be disrupted by AC or other systemic inflammatory conditions, 
leading to reduced iron availability in plasma (hypoferremia) and hence iron restricted 
anemia.30 Hypoferremia is mainly caused by tumor-induced activation of immune cells that 
release cytokines like IL-6 and IL-1b which alter iron trafficking by increasing iron retention 
inside the macrophages and reducing duodenal iron absorption.31 The iron metabolism in 
inflammatory conditions is mainly altered by interleukin-6 (IL-6),32 which induces, through 
JAK2 and STAT2 signaling,33 the synthesis of the liver peptidic hormone hepcidin. Hepcidin 
is the master regulator of the systemic iron metabolism and exerts its function by binding to 
ferroportin (Fig. 2), the only known iron exporter, and it causes its internalization and 
degradation.34 Besides inflammatory stimuli, hepatocytic hepcidin production is induced when 
iron levels are high, and reduced by erythroid activity in bone marrow through the production 
of different factors, especially erythroferrone (Erfe).33 Hepcidin blocks iron absorption in the 
duodenum and iron release from cells, especially hepatocytes and macrophages. Macrophages 
recycle iron from the senescent erythrocytes, which is the main source of iron for the 
erythropoiesis.35  Inflammation-induced levels of hepcidin cause an iron entrapment inside the 
cells, which reduces the iron concentration in plasma and thus, limits the iron available for the 
synthesis of hemoglobin ultimately causing iron restricted erythropoiesis.  
In situations of anemia and stimulated erythropoiesis by Epo action, some erythroid precursors, 
specially proerythroblasts and erythroblasts, secrete Erfe, an hormone that inhibits hepcidin 
production in order to have more bioavailable iron for the boosted erythropoiesis.36 
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Figure 2 
  
Fig. 2: Systemic iron metabolism regulation by hepcidin. Hepcidin-ferroportin (Fpn) interaction determines the flow of iron 
into the plasma. Hepcidin causes internalization and degradation of ferroportin. The gene expression of hepcidin is induced by 
iron as well as inflammation and suppressed by erythropoietic signaling. (Image taken from Nemeth, E. & Ganz, T. The Role 
of Hepcidin in Iron Metabolism. Acta Haematol. 122, 78 (2009)). 
Although the hepcidin-ferroportin pathway is the main regulator of iron levels in plasma,34,35,37 
and therefore responsible of the iron-restricted erythropoiesis and the characteristic 
hypoferremia and hyperferritinemia observed in anemia of inflammation, other mechanisms are 
also involved in inflammation-induced changes in iron homeostasis. For example, tumor 
necrosis factor-alpha (TNF-a) reduces duodenal iron absorption through an hepcidin-
independent, mechanism.38 IL-1, IL-6, IL-10, or TNF-a promote iron acquisition into 
macrophages via transferrin receptor–mediated endocytosis, via divalent metal transporter 1 
(DMT-1), or possibly also via increased iron acquisition by lactoferrin and lipocalin-2.39 
Additionally, bacterial lipopolysaccharides and interferon-g (IFN-g) block the transcription of 
ferroportin, thereby reducing cellular iron export.40,41 Other factors impacting on iron 
metabolism are the reduced synthesis of transferrin, the iron-transport protein in plasma and the 
stimulation of ferritin production facilitating the intracellular storage of iron.42 
 
 
 
 Nemeth/Ganz
 
 Acta Haematol 2009;122:78–86  80
iron deficiency anemia and most died at birth indicating 
that hepcidin also inhibited the placental transport of 
iron  [6] . Hepcidin also appears to block, at least partially, 
the export of stored iron from hepatocytes as indicated 
by hepatic iron accu ulation in mice carrying hepcidin-
overproducing tumors.
 Hepcidin derived from extrahepatic sources may also 
exert control over local iron fluxes within tissues in which 
hepcidin is produced. For example, the central nervous 
system is separated from th  plasma by the blood-brain 
barrier, and circulating hepcidin may not be transported 
across this barrier. However, brain tissue itself was re-
ported to express hepcidin, allowing the possibility of 
iron regulation independent of the systemic control.
 Mech nism of Hepci in Action 
 Hepcidin acts by modulating cellular iron export 
through ferroportin to plasma and extracellular fluid 
( fig. 2 ). Ferroportin is both the hepcidin receptor and the 
only known cellular iron exporter in vertebrates. Ferro-
portin is expressed on cells that act as professional iron 
handlers in the body: duodenal enterocytes absorbing di-
etary iron, macrophages in liver and spleen recycling old 
erythrocytes, hepatocytes storing iron and placental tro-
phoblasts transferring iron to the fetus during pregnancy 
 [7] . Ferroportin is also expressed in erythroid precursor 
cells, and it has been proposed that its presence enhances 
the sensitivity of precursors to systemic iron levels and 
helps determine their commitment to expansion and dif-
ferentiation  [8] . The complete loss of ferroportin expres-
sion in zebr fish and mouse models was shown to be em-
bryonic lethal due to the inability of embryonic tropho-
blasts to transfer iron from the mother to the embryo. In 
the selective ferroportin knockout mice that preserved 
placental ferroportin, the newborn mice lacking ferropor-
tin developed severe iron deficiency anemia due to low 
dietary iron absorption, and defective release of iron from 
hepatic storage and iron-recycling macrophages  [7] .
 Posttranslational control of ferroportin levels by its li-
gand hepcidin is the major mode of ferroportin regula-
tion. The binding of hepcidin to ferroportin triggers the 
internalization and degradation of the receptor-ligand 
complex  [9] ( fig. 3 ). The binding likely involves disulfide 
exchange between one of disulfide bonds of hepcidin and 
 Fig. 2. Hepcidin-ferroportin (Fpn) interaction determines the 
flow of iron into plasma. Hepcidin concentration is in turn regu-
lated by iron, erythropoietic activity a d inflamm ti .  
 Fig. 3. Hepcidin binding to ferroportin causes internalization of 
the receptor-ligand co plex, and their eventual degradation. 
HEK293 cells expressing ferroportin-GFP were treated with Texas-
red-labeled hepcidin and imaged using flu rescent microscopy. 
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Alterations in the erythropoiesis 
The human body generates 2 million new RBC per second via erythropoiesis.43 Erythropoiesis 
is a dynamic, complex, multistep process occurring in the bone marrow, where multipotent 
hematopoietic stem cell (HSC) differentiate into new RBC (Fig. 3).44 How RBC differentiate 
from hematopoietic pluripotent cells to mature red blood cells is a matter of debate45 and several 
models have been proposed to describe hematopoiesis (Fig. 4). Immature hematopoietic 
progenitors are capable of giving rise to multilineage colonies. They undergo a differentiation 
process where they gradually diminish their proliferative and lineage potential. HSC 
differentiate to the common myeloid progenitor (CMP) which can further differentiate into the 
erythroid or the granulocytic lineage. Along the erythroid development path CMP develop into 
megakaryocytic-erythroid progenitor (MEP) and finally into the burst-forming unit-erythroid 
(BFU-E), which is the first progenitor committed solely to the erythroid lineage.46 BFU-Es 
further differentiate into the colony forming unit-erythroid (CFU-E), which enter the terminal 
differentiation and RBC maturation.43 Late erythroid maturation involves the differentiation of 
proerythroblasts into erythrocytes undergoing through different stages characterized by the 
gradual accumulation of hemoglobin, progressive decrease in cell size and nuclear 
condensation.47 Finally, the enucleation results in the reticulocytes, which are released to the 
blood stream where they mature to red blood cells (Fig. 3).  
 
Figure 3 
 
Fig. 3: Overview of the erythropoiesis. Hematopoietic stem cell (HSC) differentiate to burst-forming unit-erythroid (BFU-
E), first progenitor cells committed solely to the erythroid lineage which further differentiate into the colony forming unit-
erythroid (CFU-E) and proerythroblasts. Late erythroid maturation which occurs in the erythroblastic islands involves the 
differentiation of proerythroblasts into erythrocytes undergoing through different stages characterized by the gradual 
accumulation of hemoglobin, progressive decrease in cell size and nuclear condensation. Finally, the enucleation results in the 
reticulocytes, which are released to the blood stream where they mature to red blood cells. (Image taken from Zivot, A., Lipton 
J. M., Narla, A. & Blanc, L. Erythropoiesis: insights into pathophysiology and treatments in 2017. Molecular medicine 
(Cambridge, Mass.) 24, 11 (2018)). 
 
 
 
 
The second phase of erythroid maturation involves
the differentiation of the nucleated precursors from
proerythroblasts to basophilic, polychromatophilic and
orthochromatic erythroblasts. This phase is character-
ized by the gradual accumulation of hemoglobin,
progressive decrease in cell size and nuclear condensa-
tion ultimately resulting in enucleation (Granick and
Levere 1964).
The final phase of erythroid development involves the
maturation of the reticulocyte into erythrocytes. It is
during this stage that the erythrocyte acquires its bicon-
cav sh pe through extensiv membrane remod ling and
will circulate in the blood stream until it is removed by
the macrophages within the reticuloendothelial system
(Gifford et al. 2006).
Terminal erythroid differentiation occurs in anatomic
niches known as erythroblastic islands. Erythroblastic
islands are unique to mammalian erythropoiesis and
consist of a central macrophage surrounde by up to 30
erythroid cells at varying degrees of red cell maturation
(Lee et al. 1988). The cells range from CFU-Es to nu-
cleating erythroblasts and are the site of hemoglobin syn-
thesis by terminally differentiating erythroblasts (Bessis
1958; Bessis and Breton-Gorius 1962). The central macro-
phage functions to anchor erythroblasts within the island
and provide the cellular interactions necessary to drive
erythroid differentiation and proliferation. Furthermore,
the central macrophage has also been shown to phagocyt-
ose the extruded nucleus from terminally differentiating
erythroblasts (Seki Shirasawa 1965; Skutelsky and
Danon 1972; Bessis et al. 1978) and direct the transfer of
iron to erythroid progenitors for heme synthesis (Bessis
and Breton-Gorius 1962; Leimberg et al. 2008).
Macrophages within erythroblastic islands also help
regulate the rate of erythropoiesis via positive and nega-
tive feedback mechanisms. Macrophages secrete cyto-
kines such as insulin-like growth factor-1 that promote
erythroid proliferation and maturation (Kurtz et al.
1985; Sawada et al. 1989). Other functions for the cen-
tral macrophage are still being investigated.
At baseline, erythropoiesis occurs at a steady, but low
basal rate with approximately 1% of circulating erythro-
cytes cleared and replaced by new cells daily (Dzierzak and
Philipsen 2013). RBCs remain in circulation for approxi-
mately 120 days during which time they are continuously
surveyed by resident macrophages within the liver and
spleen (Crosby 1959). Macrophages within the spleen can
detect and remove unwanted or damaged RBCs as well as
aged RBCs at the end of their life span (Crosby 1957).
Figure 1 provides a overview of human erythropoiesis.
Regulation of erythropoiesis
A detailed description of the regulation of human
erythropoiesis is beyond the scope of the current review.
However, several key regulators will be briefly covered as
they are involved in the erythropoietic disorders dis-
cussed below.
Erythropoietin (EPO) is a humoral cytokine synthe-
sized primarily in the kidney and secreted into the blood
stream where it targets erythroid progenitor cells in the
bone marrow (Broxmeyer 2013). The primary function
of EPO is to regulate oxygen delivery to peripheral
tissues and is facilitated by the hypoxic induction of
EPO gene transcription. Multiple transcription factors
are involved in this process including hypoxia inducible
factor, regulated by the relative level of hypoxia, and
GATA binding proteins (Bunn 2013). Among the GATA
proteins, GATA-1, GATA-2 & GATA-3 have been shown
to negatively regulate the expression of EPO mRNA via
binding in the EPO promoter region (Imagawa et al.
1997). As such, the rate of EPO gene transcription is regu-
lated by the local oxygen environment. In addition to
regulating the expression of EPO mRNA, specifically
GATA-1 and GATA-2 play crucial roles in the regulation
of lineage-restricted gene expression during erythroid
differentiation. GATA-1 is necessary for the survival and
terminal differentiation of erythroid progenitors, whereas
GATA-2 regulates the maintenance and proliferation of
hematopoietic stem and progenitor cells. It is the relative
proportion of GATA-1 and GATA-2 expression, that
Fig. 1 Overview of erythropoiesis, from the hematopoietic stem cell (HSC) to the red blood cell (RBC). Erythropoiesis takes place in the bone
marrow, and erythroblastic islands are niches for erythrop iesis from the CFU-E to the reticulocyte state. Then he reticulocyte reaches the blood
stream whe e it achieves its maturation by losing its in ernal organelles, remodeling its plasma membrane and finally becomes a RBC
Zivot et al. Molecular Medicine  (2018) 24:11 Page 2 of 15
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Figure 4 
 
 
Figure 4: Different models proposed for the hematopoietic hierarchy. In the model proposed by the Weissman group48,49,50 
(solid arrows), multipotential progenitors (MPPs or short-term HSCs [ST-HSCs] give rise to either a common lymphocyte 
progenitor (CLP) or a common myeloid progenitor (CMP), which, in turn, gives rise to either a granulocyte-macrophage 
progenitor (GMP, equivalent to CFU-GM) or a megakaryocyte-erythroid progenitor (MEP). The alternate model suggested by 
the Jacobson group51 (dotted arrows) involves the generation of MEPs directly from the MPPs/ST-HSCs, whereas a lymphoid-
primed multipotential progenitor (LMPP) has the potential to generate both CLPs and GMPs. LT-HSC, Long-term 
hematopoietic stem cell; NK cell, natural killer cell. (Image taken from Dzierzak, E. & Philipsen, S. Erythropoiesis: 
development and differentiation. Cold Spring Harb. Perspect. Med. 3, 1–16 (2013)). 
 
These steps of hematopoiesis (including erythropoiesis), i.e. the production of the different 
cellular types which constitute the blood, are governed by multiple cytokines that promote 
survival, proliferation an differentiation of HSC and progenitor cells.52 Among the cytokines,  
Epo and stem cell factor (SCF) are key regulators of erythropoiesis. Impaired erythropoiesis 
because of cancer inflammation can be caused by distinct mechanisms: e.g. reduced expression 
of Epo in the kidney, inhibition of Epo the biological activity,53 or to inhibition of SCF 
production.25  
Epo is a glycoprotein hormone synthesized in response to tissue hypoxia principally in 
interstitial fibroblasts and the proximal tubular cells of the kidney but also in minor extend in 
the liver in mice.54 Its synthesis and release in plasma is regulated by tissue oxygen tension 
through hypoxia-inducible factor 2 (HIF-2) activity, and its main function is to stimulate RBC 
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production in order to compensate the hypoxia.55 Epo binds to its receptor (EpoR) on the 
cellular membrane of the erythroid precursors in the bone marrow. The binding of Epo to its 
receptor promotes the proliferation and differentiation of the erythroid cells and inhibits their 
apoptosis mainly through the activation of the JAK-STAT signal transduction pathways.56 
EpoR is also expressed in other tissues and cells such as endothelial cells, neurons and 
myocardial cells where EpoR promotes cell repair an inhibits apoptosis.57,58 Some studies in 
anemia of chronic disease showed lower Epo levels than expected for the severity of the anemia 
in most of the subjects.23 Some cytokines, mainly IL-1 and TNF-a are known to inhibit Epo 
production by interfering with mediated GATA-2 or HNF4 transcription or by causing radical-
mediated damage of Epo-producing kidney epithelial cells.59,60 Additionally, proinflammatory 
cytokines, especially IL-6 and IL-1 also inhibit Epo function by impairing EpoR downstream 
signaling.61 Furthermore, some cytokines like INF-g, interleukin-10 (IL-10), granulocyte-
colony stimulating factor (G-CSF) and IL-6 stimulates the production of the suppressor of 
cytokine signaling-3 (SOCS-3) which binds to JAK kinase and to EpoR resulting in the 
inhibition of the STAT3 activation.62 Moreover, INF-g, TNF-a and IL-1 can also target directly 
erythroid progenitors inducing apoptosis, inhibiting differentiation and proliferation of 
erythroid progenitor cells63,25 and promoting differentiation of myeloid cells progenitors.64,65  
Stem cell factor (SCF) also has a main role in the control of hematopoiesis.66 In the bone 
marrow, it is produced by endothelial cells67 and fibroblasts and binds to its receptor, c-kit.68,69 
SCF is essential for the maintenance of normal basal hematopoiesis and is also required for 
acute erythroid expansion during the recovery from anemia in adult mice.70 It acts in 
conjunction with other cytokines and especially in coordination with Epo promoting the 
survival and expansion of stem cells as of as the expansion, survival  and differentiation of 
different progenitors.71  Other important hematopoietic regulators are interleukin-3 (IL-3) or 
common colony stimulating factor (CSF), granulocyte colony stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM-SCF) which stimulates proliferation 
and differentiation of multiple progenitors specially granulocytes.52 
Despite the direct inhibition of erythropoiesis, iron supply in bone marrow also act as a 
regulator of the hematopoiesis, being necessary for the differentiation of the later stages of 
erythropoiesis through the synthesis of heme group and regulating the transcription of 
hemoglobin genes.72  
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Alterations on the nutritional and metabolic state 
Some of the immune system alterations associated to the tumor disease in cancer patients have 
effects in multiple organs and cause multiple symptoms as anorexia, vomits, loss of body 
weight and cachexia of cancer, reduction of muscle mass, increase in the resting energy 
expenditure with alterations in glucose, lipid and protein metabolism, fatigue and 
immunosuppression.24 The severity of the immune alterations is proportional to the cancer stage 
and to the amount of inflammatory cytokines.73,74 It has been shown that IL-6 levels are 
inversely correlated with albumin levels and cachexia in patients with lymphoma75 and it has 
been related with the severity of weight loss in cancer patients.24 Moreover, other 
proinflammatory cytokines as TNF-a, IL-1 and INF-g have been related with weight loss and 
metabolic alterations in cancer patients,76 by increasing the metabolic rate through activation 
of thermogenesis, inhibiting adipocyte and skeletal myocyte differentiation and reducing the 
food intake.77 These alterations on the nutritional and the metabolic status of the cancer patients 
might affect the levels of iron, glucose, vitamins and other micronutrients useful for the 
erythropoiesis and therefore contribute on the pathogenesis of the AC.24 Hence, it is important 
to take them in consideration for the diagnostic and treatment plan of the cancer related anemia. 
 
3.3. Therapeutic approach of AC 
Despite the high prevalence of AC and its important clinical significance, AC is currently 
undertreated and no specific aimed treatments for this kind of anemia have been yet approved.24 
Due to its multifactorial nature, it should be efficiently treated using multitargeted therapies. 
Before starting the treatment in a particular patient, an exhaustive evaluation of all the potential 
contributors to the anemia should be performed in order to target every treatable cause. 
Currently, the National Comprehensive Cancer Network (NCCN) provided a guideline for 
cancer- and chemotherapy induced anemia diagnosis and management.78 It is important to keep 
in mind though, that anemia reflects the severity of the neoplastic disease, and the cure of cancer 
is so far the only way to cure anemia. A curative treatment of the cancer is not always possible 
and therefore, an individualized therapeutic strategy might be required to palliate the anemia 
and its multiple consequences in human cancer patients.79  The drugs and therapeutic 
procedures most commonly used for the treatment of AC are: blood transfusions, 
erythropoiesis-stimulating agents (ESA), iron supplementation, nutritional supplementation 
and anti-inflammatory therapies.23 Other agents that could be useful in the future include 
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hepcidin antagonists, iron-chelators therapy and use of cytokines and hormones that could 
modulate the erythropoiesis under inflammatory conditions.24 
 
Blood transfusions 
Red blood cells transfusions are a fast and effective method to increase hemoglobin levels, 
palliate anemia associated symptoms and improve quality of life in cancer patients. However, 
this treatment has some limitations like the limited availability of the blood products or the fact 
that some patients are unable to receive blood transfusions due to the presence of multiple 
alloantibodies or to their specific religious beliefs.78 Moreover, blood transfusions have some 
associated risks, including fever, transfusion related allergic reactions, transmission of 
infectious diseases, alloimmunization, iron overload and immunosuopression.20,80 Additionally 
they have been associated with multiorgan failure and increased mortality in patients under 
critical care.81 Whether blood transfusions modulate the immune system, causing clinically 
relevant adverse effects, remains still undetermined.82 Therefore, blood transfusions should be 
used only in patients with symptomatic or severe anemia who need a fast increase in the oxygen 
transport capacity.78 
 
Erythropoiesis-stimulating agents (ESA) 
Recombinant human erythropoietin (huEPO) is approved for treating anemia in patients with 
chronic kidney disease and anemia in cancer patients due to the chemotherapy. Despite not 
being specifically approved for the treatment of AC, the capacity of huEPO treatment in cancer 
patients to increase hemoglobin levels, reduce the need for blood transfusions and improve 
their quality of life has been demonstrated in several studies.83,84,85 In general, ESA alone have 
a responsiveness rate among cancer patients presenting anemia of 55-65%83 and increases to 
70-90% when it is used in combination with iron supplementation.86,87,88,89 Additionally, ESAs, 
due to its action in other organs, may have other systemic actions which might be beneficial, 
like a neuroprotective and anti-inflammatory effect as of as vascular and metabolic actions.90,23 
Currently, there are several forms available (epoetin alfa, epoetin beta, and darbepoetin alfa) 
with similar efficacy but different half-life after administration.91,92 
However, concerns about huEPO safety have been raised because some studies showed that 
ESAs treatment in cancer patients is associated with an inferior survival and worse cancer 
outcomes.93,94 However, these results are controversial since other analysis failed to confirm 
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these data.95  Systematic reviews demonstrated a significantly higher risk of thromboembolic 
events in patients receiving ESAs for AC,96,97,83,98 but again, some others pointed that this 
increased mortality could be related to the design of the studies, setting excessively high 
baseline hemoglobin levels before starting the treatment 99,100 and too high target hemoglobin 
levels.101,102 Other adverse side effects of ESA treatment as hypertension, thrombocytopenia, 
hemorrhage and seizures have been also reported.83 Additionally, due to the fact that EpoR is 
found in multiple cancer cell types,103,21,104 it was hypothesized that the increased mortality 
could be due to the ability of Epo to stimulate tumor growth.105,106 Indeed, some in vitro 
studies have shown that Epo is able to increase cell proliferation,107 induce resistance to 
apoptosis108 and promote cell migration.109 In addition, some in vivo studies investigating 
the effect of ESA in tumor progression  showed that ESAs were associated with increased 
tumor growth,21,110 and it was hypothesized that it might be due to induction of 
neoangiogenesis, since Epo increases inflammation and ischemia-induced neovascularization 
by enhancing the mobilization of endothelial progenitor cells.111 Due to all the aforementioned 
concerns about the safety of ESA treatment in cancer patients, these drugs should be used 
with caution. 
 
Iron supplementation 
Iron deficiency is a common comorbidity in cancer patients, affecting 29%-60% of this kind 
of patients.112 Determination of the iron status is recommended before starting the treatment 
with ESA because erythropoiesis requires bioavailable iron, and lack of iron can lead to a 
fail of the treatment.88 Patients might be classified as: iron replete, having absolute iron 
deficiency (ferritin <30 ng/dL, transferrin saturation <15%), or having functional iron 
deficiency (ferritin 30–800 ng/dL and transferrin saturation <20%).113,114 Patients with 
absolute iron deficiency may be treated with iron supplementation only, while those with 
functional iron deficiency should receive ESAs along with parenteral iron.114 Despite oral 
and parenteral iron forms are available in the market to treat iron deficiency, several studies 
have shown than parenteral iron is more effective for patients with cancer and functional 
iron deficiency.115,116,117 Some studies showed that the addition of iron supplementation to 
the anemia treatment with ESA had greater increments in hemoglobin levels and the need 
for transfusion was reduced,116,87,86 but still limited data about iron efficacy as monotherapy 
are available.118 It is important to note though, that another study demonstrated a lack of 
benefit of adding intravenous iron to ESAs in anemic cancer patients with signs of functional 
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iron deficiency.119 However, for patients with functional iron deficiency with high levels of 
ferritin (low circulating iron in plasma but replete iron stores), iron supplementation is not 
recommended since iron overload can cause ROS induction and aggravate the oxidative 
stress status leading to subsequent endothelial damage and increased risk of cardiovascular 
complications.24 It is also important to mention that there are some safety concerns regarding 
iron supplementation in cancer patients. Besides the common adverse effects of parenteral iron 
administration as flushing, nausea, vomiting, diarrhea120 and increased risk of infections,121 it 
has been shown that iron has a role in all aspects of cancer development, including tumor 
initiation, growth and on the tumor microenvironment and metastasis.122 It has been 
demonstrated in several animal studies that, in different types of cancer, excessive iron 
supplementation could  lead to increased cancer cell proliferation.123 Therefore, with the current 
data available, the iron status of patients with AC should be evaluated and supplemented when 
needed, especially those who does not respond to ESAs therapy alone.24  
 
3.4 Mouse models of AC 
 
Although AC is highly present in patients who suffer from cancer with a major clinical 
relevance for disease prognosis and treatment, this condition is still currently undertreated due 
in a great extent to the lack of safe treatment options.124 Therefore there is a growing interest in 
characterizing new contributing factors to AC and finding new targets for its treatment. 
Preclinical models should contribute to the better understanding of the complex 
pathophysiology of this kind of anemia and facilitate the development of safer and more 
effective treatment strategies.125 However, very few animal models for AC have been 
developed, all of them being injected tumor models (orthotopic models). Two of them are 
murine xenograft models were the alteration of the iron metabolism due to upregulation of 
hepcidin by IL-6 was studied and the efficacy of an IL-6 antibody (MR16-1) to mitigate the 
anemia was evaluated.126,127 In another study, four synergic murine models, in which different 
tumor cells lines were injected into C57BL/6 mice, were characterized and the role of the 
inflammation and hepcidin on the AC was studied, getting different degrees of hepcidin 
involvement for each model, illustrating the great variability of the importance of the different 
etiological factors in the pathogenesis of AC.125 Additionally, in another murine tumor model 
with 4T1 injected cancer cells, they showed that tumor was blocking medullar erythropoiesis 
through the production of granulocyte colony-stimulating factor (G-CSF). Additionally, they 
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showed the involvement of macrophages in the splenic erythropoiesis promoted by the tumor 
stress, which in turns, also have a role in promoting the tumor grrowth.128   
To our knowledge, no genetically engineered animal models with spontaneous tumor 
development have been investigated. Our Trp53floxWapCre mouse model is selectively 
deficient of the p53 tumor suppressor gene in luminal cells of the mammary tissue.129 The 
deletion of this gene causes the spontaneous development of mammary tumors and AC. 
Alterations in the p53 gene are very common in human breast cancer.130  Therefore, we tested 
if our transgenic Trp53floxWapCre mouse model, might be a new model to investigate AC and 
if it might help to the better characterization and understanding a of this multifactorial and 
complicated condition helping to develop and evaluate safer and more effective therapeutic 
approaches. 
 
3.5 Rational and objectives 
AC has a huge clinical impact on cancer patients, not only impairing their quality of life and 
limiting their antineoplastic treatment options but also contributing to the disease progression. 
Nowadays, effective and safe treatment approaches are still lacking, and this is one of the main 
reasons why it is still in great extend left undertreated. Very few mice models of AC have been 
characterized and, to our knowledge, none of them being a model with spontaneous tumor 
development. The use of preclinical models can contribute to better understand this 
multifactorial and complex condition and help to design safer and more effective treatments. 
We characterized AC in Trp53floxWapCre mice and analyzed if this model reflects the 
pathology of impaired erythropoiesis in AC of human patients and if it is useful to test multiple 
treatment approaches. We therefore focused on: 
I) Defining the inflammatory response and the alterations in the iron metabolism  
II) Testing the efficacy of iron supplementation 
III) Analyzing the impact of cancer in hematopoiesis and erythropoiesis  
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4. Material and methods 
4.1 Animal Experiments  
Housing conditions 
Mice were housed at 22±5 °C in a 12 h light/dark cycle and fed either with a standard rodent 
chow (250 mg/kg iron) (Kliba Nafag, #3436) or with an iron sufficient diet (50 mg/kg iron) 
(Kliba Nafag, #2222 modified) and water ad libitum. The experiments were performed in 
accordance with the Swiss animal law and with the approval of the ethical committee of the 
respective local authorities (Kanton Zurich).  
 
Mouse models 
Spontaneously tumor-developing mouse model. In this study, we used transgenic 
Trp53floxWapCre mice129 bred in our animal facilities in which the tumor suppressor gene p53 
was deleted specifically from the mammary tissue using Cre/lox system. The genetic 
background of the mice used for the genetic modification was FVB wildtype.  
FVB wild type. FVB wildtype mice were purchased from Envigo (Netherlands) at the age of 
12 weeks. They were housed in our animal facility in the same conditions than Trp53floxWapCre 
mice. At the age of 26-27 weeks plasma and organs were collected in order to compare iron 
parameters in plasma and tissue with Trp53floxWapCre mice to discard aberrant iron metabolism 
modifications in our transgenic strain. 
Allotransplanted tumor mouse model. Immunocompromised Foxn1nu mice of 8-9 weeks of 
age were purchased form Envigo (Netherlands) and housed in our facilities. Between 11-14 
weeks of age they were anesthetized with isoflurane, and to 5 mice a fresh piece of 
approximately 3 mm3 of a mammary tumor (>1cm3) from a Trp53floxWapCre previously 
euthanized using CO2 was placed subcutaneously for allographic tumor transplantation. The 
skin was closed using 4/0 polypropylene surgical suture. 5 animals were sham operated in order 
to use as a control. All the tumors grew, but 3 out of 5 animals developed ulcers on the tumor 
site before reaching termination criteria and therefore they had to be euthanized before reaching 
the maximal tumor size.  
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Procedures 
Tumor detection and measurement. Mice were monitored by visual observation and 
palpation every other day from 18 weeks of age or from tumor implantation until a tumor was 
found. After tumor detection, tumor length (L) and width (W) were measured every other day 
using a caliper and tumor volume (V) was calculated as [V = (L × W2)/2].131 Bodyweight was 
also measured every other day in tumor-bearing mice. 
Epo treatment. Mice were manually restrained and subcutaneously injected with 1000 U/kg 
of Epo (Recormon, Roche) or saline 3 times a week beginning the first day of tumor detection 
with a 30 G BD micro-fine insulin syringe. Animals were euthanized when the tumor reached 
the maximal permitted tumor size of 2 cm3 (single tumor) or 3 cm3 (total volume of multiple 
tumors). 
Iron treatment experiment. In the first experiment, mice were injected intravenously (i.v.) 
with either saline or 13,8 mg/kg of ferric carboxymaltose (Ferinjectâ) the same day than the 
tumor was detected. The dose of ferric carboxymaltose was calculated using the Ganzoni 
formula:132  
Total iron deficit [mg] = BW [kg] x (target Hb - actual Hb) [g/dl] x 2.4) + storage iron [mg]   
BW was the body weight of mice at the moment of the tumor diagnosis, target Hb refers to the 
upper 75% percentile of hemoglobin values in the tumor free control group and the actual Hb 
was the 25% percentile of hemoglobin vales of tumor-bearing mice when they reached maximal 
permitted tumor size of 2 cm3 (single tumor) or 3 cm3 (total volume of multiple tumors). Ferric 
carboxymaltose volume was diluted in 0.9% NaCl up to 100 µl of total volume solution. Mice 
were restrained in a self-made restrainer and the tail was placed into a warm water bath (30 - 
35 °C) for around 3 minutes to dilate the tail veins. One of the lateral veins was injected using 
a 30 G BD micro-fine insulin syringe. Mice were euthanized when the tumor reached maximal 
permitted size of 2 cm3 (single tumor) or 3 cm3 (total volume of multiple tumors). 
Alternatively, in subsequent experiments, mice were i.v. injected with 20 mg/kg instead of 13.8 
mg/kg of ferric carboxymaltose (Ferinjectâ) or saline and either directly after tumor detection 
or when tumor size reached 1.5 cm3.   The experiment was terminated exactly 15 days after the 
i.v. injection in mice that received the injection after tumor development or 48 h after injection 
in mice that received the injection when the tumor reached a size of 1.5 cm3.  
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Perfusion and sample collection. Tumor-bearing mice were euthanized by carbon dioxide 
(CO2) at different stages of the disease: the same day of the tumor diagnosis (day 0), 7 days 
(7d) and 15 days (15d) after tumor diagnosis, or at end stage (ES): when they reached 
experimental termination criteria by maximal tumor permitted size (tumor volume of 2 cm3 for 
single tumor or 3 cm3 for multiple tumors). Tumor free age-matched animals were also 
euthanized and used as control. Immediately after euthanasia, the chest cavity of the mice was 
opened to expose the heart and 0.5-1 ml blood was collected by cardiac puncture into the right 
ventricle with a 1 ml syringe coated with heparin. The mice were then transcardially perfused 
with 20 ml ice-cold PBS by introducing a needle into the left ventricle of the heart after 
perforating the right atrium.  
The organs listed in Table 1 were immediately collected, weighed, cut and appropriate stored 
either in 4% paraformaldehyde (PFA) at room temperature for fixation and future histology 
use, or snap frozen in liquid nitrogen and stored at -80 °C for future quantificational analysis. 
Tissues incubated for 24-48 h in 4% PFA were then washed twice in 1x PBS and placed in 70% 
EtOH for longer storage at 4 °C.  
Bone marrow from both femurs and tibias were collected by flushing the bone marrow cavity 
using a 1 ml syringe attached to a 24 G needle either with RPMI medium supplemented with 
2.5% heat-inactivated FBS for the flow cytometry experiments, or with the LBA-TG buffer 
from the ReliaPrep® RNA Tissue Miniprep System and snap frozen for the subsequent RNA 
isolation.  
Table 1: Overview of collected samples 
Samples 4% PFA Snap Frozen (80°) 
Plasma  entire 
Tumor (1st tumor detected) 1/2 1/4 
Spleen 1/2 1/2 
Liver left lateral lobe rest 
Kidney right left 
Lungs entire  
Bone marrow (2 femurs and 2 tibias)  entire 
Sternum entire  
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4.2 Analyzing mRNA expression by real time PCR  
RNA extraction. RNA of harvested tissue, namely liver, spleen, kidney, tumor, healthy 
mammary tissue and bone marrow, was extracted using the ReliaPrep® RNA Tissue Miniprep 
System (Promega) following the supplier instructions. RNA concentration and purity (260/280 
nm) was measured on the NanoDrop 2000 Spectrophotometer and RNA samples were stored 
at -80 °C or directly transcribed into cDNA.  
Complementary DNA synthesis. 500 ng RNA was diluted in 10.5 µl sterile H2O and 2 µl of 
Oligo-dT (10 µM) was added, gently mixed, centrifuged, incubated at 65 °C for 5 min and then 
put on ice immediately. 7.5 µl of the master containing 4 µl of 5x Reaction Buffer (Thermo 
Fisher), 0.5µl Thermo Scientific
TM RiboLock RNase inhibitor (20 U), 2 µl dNTP Mix 10 mM 
(Thermo Scientific) and 1 µl RevertAid Reverse Transcriptase 200 U (Thermo Scientific) was 
added to each sample and incubated for 60 min at 42 °C. To heat-inactivate the RNase, the 
reaction was terminated by incubating the samples at 70 °C for 10 min. To obtain a cDNA 
concentration of 5 ng/µl, 80 µl of H2O was added and the cDNA was stored at -20 °C.  
Primer Design. Primers were designed with Primer3 software as described by Rozen et al.133 
and purchased at Microsynth (Switzerland). Used primers are shown in Table 2. 
Real time PCR. Master mix was prepared on ice containing 5 µl LightCycler 480 SYBR Green 
I Master (Roche Applied Science, Cat. 04707516001), 1 µl Primer forward (10 µM), 1 µl Primer 
reverse (10 µM) and 1 µl H2O per sample. Samples were run in duplicates and 2 µl cDNA (5 
ng/µl) was added to 8 µl master mix per well, in a MicroAmp Fast Optical 96-Well Reaction 
Plate (Applied Biosystems by life technologies) on ice. Plate was sealed with Optical Adhesive 
Covers (Applied Biosystems by Life Technologies), and centrifuged for 2-3 minutes at 2500 x 
g, before being placed in Thermocycler ABI7500 Fast (Applied Biosystems) to run Real-time 
PCR. The program for cDNA amplification was set to: 50° C for 2 min; 95° C for 10 min; 40 
cycles at 95° C a 30 sec and 60° C for 40 sec, followed by melt curve analysis. Fold changes 
were determined by delta-delta Ct method134 with beta-Actin or Gypa (Glycophorin A), for 
some genes measured in bone marrow and spleen, as reference gene. 
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Table 2. Primer sequences for genes analyzed with Real-time PCR (SYBR green method) 
Target Gene Primer Pair ! -actin 
Reference gene  
Fwd: 5’CAACGGCTCCGGCATGTGC3’ 
Rev: 5’ CTCTTGCTCTGGGCCTCG 3’ 
Epo 
Erythropoietin 
Fwd: 5’ AGACAAAGCCATCAGTGGTC 3’ 
Rev: 5’ TGTGAGTGTTCGGAGTGGAG 3’ 
IL-6 
Interleukin-6 
Fwd: 5’CTCTGGGAAATCGTGGAAAT3’ 
Rev: 5’ CCAGTTTGGTAGCATCCATC 3’ 
SAA-1 
Serum amyloid A1 
Fwd: 5’ GGGGAACTATGATGCTGCT 3’ 
Rev: 5’ ATTGGGGTCTTTGCCACT 3’ 
IL-1" 
Interleukin-1! Fwd: 5’ CCTGTGTAATGAAAGGCA 3’  Rev: 5’ CTGCTTGTGAGGTGCTGATG 3’ 
TNF⍺ 
Tumor necrosis factor ⍺ Fwd: 5’ ATCAAGGACTCAAATGGGCTT 3’  Rev: 5’ GCAACCTGACCACTCTCCCT 3’ 
Hamp-1 
Hepcidin-1 
Fwd: 5’ TTCCCAGTGTGGTATCTGTTG 3’ 
Rev: 5’ GGGAGGGCAGGAATAAATAAT 3’ 
Fpn 
Ferroportin 
Fwd: 5’ ACC CAT CCC CAT AGT CTC TGT 3’ 
Rev: 5’ CCG TCA AAT CAA AGG ACC AA 3’ 
Fth1 
Heavy chain ferritin 
Fwd: 5’ GCCAGAACTACCACCAGGAC 3’ 
Rev: 5’ TTCAGAGCCACATCATCTCG 3’ 
Trf 
Transferrin 
Fwd: 5’ CACACACACCGAGAGGATGA 3’ 
Rev: 5’ TTCTCGTGCTCTGACACTGC 3’ 
BMP-6 
Bone morphogenic protein-6 
Fwd: 5’ TGTGATGGAGAGTGTTCC 3’ 
Rev: 5’ GGCATTCAGTTTGGTTGG 3’ 
Hfe2 
Hemojuvelin 
Fwd: 5’TTGCTAGATAACGACTTCCTCTTTG3’ 
Rev: 5’AGCCTGGTAGACTTTCTGGT3’ 
Hfe 
Homeostatic iron regulator 
Fwd: 5’ TGCTACCTAACGGGGATGAG 3’ 
Rev: 5’ GACGGTGACTCCACTGATGA 3’ 
TfR-1 
Transferrin recepror-1 
Fwd: 5’ GAGACTACTTCCGTGCTACT 3’ 
Rev: 5’ GGAGACTCT CTTGGAGATAC3’ 
TfR-2 
Transferrin recepror-2 
Fwd: 5’ CTGCGGAAGGAGATTTACAG 3’ 
Rev: 5’ ACTGGGACAGGAAGTAGAAC 3’ 
Erfe 
Erythroferrone 
Fwd: 5’ AGCGAGCTCTTCACCATCTC 3’ 
Rev: 5’ TGTCCAAGAAGACAGAAGTGTAGTG 3’ 
Epo-R 
Erythropoietin receptor 
Fwd: 5’ GTCCTCATCTCGCTGTTGCT 3’ 
Rev: 5’ CAGGCCAGATCTTCTGCTG 3’ 
Hb⍺ 
Hemoglobin ⍺ chain Fwd: 5’ TGAAGCCCTGGAAAGGATGTTTG 3’ Rev: 5’ CCTTCTTGCCGTGACCCTTG 3’ 
Hb" 
Hemoglobin ! chain Fwd: 5’ CGATGAAGTTGGTGGTGAGG 3’ Rev: 5’ ATAGCAGAGGCAGAGGATAGG 3’ 
Gypa 
Glycophorin A 
Fwd: 5’ ATGGCAGGGATTATCGGAAC 3’ 
Rev: 5’ CACCCTCAGGAGATTGGATG 3’ 
SCF 
Stem cell factor 
Fwd: 5’ TGGGAAAATAGTGGATGACCTCGTGT 3’ 
Rev: 5’ CGGGACCTAATGTTGAAGAGAGCACA 3’ 
SOCS-3 
Suppressor of cytokine signaling 3 
Fwd: 5’ TCACCCACAGCAAGTTTCCC 3’ 
Rev: 5’ GCTCCAGTAGAATCCGCTCTC 3’ 
G-CSF 
Granulocyte colony-stimulating factor  
Fwd: 5’ GCAGGCTCTATCGGGTATTT 3’ 
Rev: 5’ TGGAAGGCAGAAGTGAAGG 3 
GM-CSF 
Granulocyte-macrophage colony-
stimulating factor 
Fwd: 5’CTCACCCATCACTGTCACCC 3’ 
Rev: 5’GACGACTTCTACCTCTTCATTCAAC3’ 
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4.3 Analyzing plasma Epo concentration 
For the quantitative determination of Epo concentration in plasma, we used Quantikineâ ELISA 
Mouse Erythropoietin Immunoassay (#MEP00B) from R&D Systems, Inc. The protocol 
provided by the manufacturer was thoroughly followed. The optical density was determined 
with BioTeck Epoch™ 2 Microplate Spectrophotometer at 450 nm. Absorbances were 
corrected by subtracting the values of 540 nm from the values if 450 nm. Results were 
calculated by extrapolation of the standard curve which was calculated by four-parameter 
logistic (4-PL) regression. 
 
4.4 Hematology and Clinical biochemistry 
Hemoglobin was measured from fresh hole blood collected by cardiac puncture by ABL800 
(Radiometer RSCH GmbH). Hematocrit was determined with blood-filled capillaries by 
measuring the ratio of the volume occupied by red blood cells to the volume of whole blood 
after 5 min at 120 rpm in the microcentrifuge (HETTICH). The rest of the blood was used for 
plasma extraction by centrifuging the blood at 2000 rpm for 10 minutes. The clear supernatant 
was removed and filled into a new tube to be snap frozen.  
Hematology was performed in fresh hole blood collected by cardiac puncture and stored in 
EDTA coated tubes at 4°C. Analysis were performed using the Sysmex XT-2000iV within 1 
hour after collection. 
For clinical biochemistry, hole blood was collected by cardiac puncture with a heparin coated 
needle and kept in 1.5 ml microcentrifuge tubes at 4°C. Plasma was extracted by centrifuging 
the blood at 2000 rpm for 10 minutes. Analysis were performed with Roche Integra 800 
analyzer within 1 hour after collection and following parameters were measured: bilirubin, 
glucose, urea, creatinine, total protein, cholesterol, triglycerides, alkaline phosphatase, aspartate 
transaminase and alanine transaminase. 
 
4.5 Histology  
Tissue embedding. Tissues stored in 70% EtOH were placed in paraffin embedding cassettes 
and chemical fixed in the Microm spin tissue processor STP-120. After embedding the tissues 
in paraffin blocks, the paraffinized tissues were cut in 3-5 µm sections.  
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Hematoxylin and Eosin (H&E) staining. Slides were deparaffinized in xylene, rehydrated 
through graded alcohols of decreasing concentrations, stained with hematoxylin and eosin and 
dehydrated again using increasing alcohol concentrations. All steps were performed using the 
automated staining system Discovery from Ventana Medical Systems, Inc. 
Perl’s-DAB enhanced staining. This stain was performed to visualize iron. The tissue sections 
were deparaffinized and incubated for 2 minutes in a solution 1:1 of 2% potassium ferrocyanide 
and 2% HCl. Next, they were washed with demineralized water and later with TBS. Thereafter, 
the slides were incubated for 15 minutes with the H2O2 blocking solution and washed with TBS. 
After, the slides were incubated for 5 min with DAB and washed again with water. Further, the 
slides were incubated with hematoxylin for 3 minutes and washed with tap water until they got 
a blueish coloration. To finalize, the slides were dehydrated and covered. 
Ki-67 staining. The staining procedure is used to visualize cell proliferation and it was 
performed using the automated staining system Discovery from Ventana Medical Systems, Inc. 
Slides were deparaffinized in xylene and rehydrated trough graded alcohols of decreasing 
concentrations. After antigen retrieval slides were incubated with the primary rabbit 
monoclonal antibody Ki-67 (30-9) 1:1 from Roche (# 790-4286) for 32 minutes. The secondary 
antibody used was biotinylated donkey anti-rabbit* IgG 1:100 for 8 minutes. Discovery DAB 
Map detection kit from Roche (#760-124) was used for the antigen detection and the cellular 
background was stained with hematoxylin (incubation time of 4 min). Slides where dehydrated 
again using increasing alcohol concentrations and covered. 
 Cellular quantification. Ki-67 positive cells in the whole tissue sections of liver as well as 
cellularity of H&E stained bone marrow sections were quantified using Viopharm sofware by 
dividing the number Ki-67 positive cell or cellular nucleous by the analyzed area. 
 
4.6 Analyzing plasmatic interleukin-6 concentration 
Interleukin-6 (IL-6) concentration in plasma was determined by ELISA assay using U-PLEX 
Mouse IL-6 Assayâ (#K152TXK-1) from Meso Scale Discovery (MSD). 
Frozen heparinized plasma was thawed and centrifuged at 1000 x g for 1 min to pellet debris 
and the assay was performed according to the manufacturer recommendations. Briefly, the plate 
was coated with the biotinylated IL-6 antibody by incubating it for 1 hour at room temperature 
on a shaker at 500-1000 rpm. The plate was washed 3 times by adding 150 µl PBS-T 
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(0.05%Tween-20) to each well. Serial dilutions of the calibrator were prepared in order to 
generate the standard curve and 25 µl of diluent plus either 25 µl of plasma or standard were 
added to the correspondent well. The plate was then sealed and incubated for 1 h on the shaker 
at room temperature. The plate was rinsed again 3 times with 150 µl PBS-T and 150 µl of the 
2X read buffer were added to each well before reading the plate on the MESO QuickPlex SQ 
120 instrument (Meso Scale Discovery) with the MSD Workbench 4.0 software.  
 
4.7 Iron parameters in plasma 
Serum iron concentration was measured using the colorimetric Iron (SFBC) 
Bathophenanthrolin assay from Biolabo (#80008). Frozen heparinized plasma was thawed and 
50 µl were used for the assay, which was performed in a 96-well plate. The assay was performed 
according to the manufacturer recommendations, but volumes were proportionally reduced. 
Briefly, 50 µl of solution R1 were added to 50 ml of sample in microcentrifuge tubes and 
vortexed for 2 minutes. After 5 minutes of incubation, each tube was centrifuged for 10 minutes 
at 3000 rpm. 50 µl of the mixture was then transferred to a 96 well. To generate the blank 25 
µl of deionized water plus 25 µl or solution R1 were added to some wells, and for the standard, 
25 µl of solution R3 plus 25 µl of solution R1.  50 µl of solution R2 was added to all wells and 
the plate incubated for 5 minutes at room temperature. After incubation, the plate was read at 
535 nm in BioTeck Epoch™ 2 Microplate Spectrophotometer. For the calculation of the results, 
the following formula was used:  
Iron plasma concentration (µl g/dL) = [Abs (Assay) /Abs (Standard)] x Standard concentration. 
 
Unsaturated iron binding capacity was measured by a colorimetric method (ferene direct 
method): U.I.B.C. Unsaturated Iron Binding Capacity from Biolabo (#97408). 20 µl of thawed 
heparinized plasma was used for the assay, which was performed in a 96-well plate. The 
instructions of the manufacturer were thoroughly followed, but volumes were proportionally 
reduced. Briefly, 100 µl of solution R1 were added to each well, 20 µl of solution R2 were 
added to every well except on the blank, were 40 µl of deionized water was added instead. To 
the standard 20 µl of deionized water was added and to the rest of the wells 20 µl of sample. 
Before the addition of 2 ml of ferene (chromogen), the plate was read at 600 nm against the 
reagent blank using BioTeck Epoch™ 2 Microplate Spectrophotometer (A1). 20 min after the 
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addition of ferene, the plate was read again at the same wavelength (A2). For the calculation of 
the results, the following formula was used: 
UIBC (µl g/dL) = 500 - [500 x (A2 Assay - A1 Assay) / (A2 Standard - A1 Standard)] 
 
Total iron binding capacity (TIBC) was calculated using the following formula: 
TIBC (µl g/dL) = Plasma iron concentration (µl g/dL) + UIBC (µl g/dL) 
 
Transferrin saturation (Tsat) was calculated using the following formula: 
Tsat (%) = (Iron concentration in plasma / TIBC) x 100 
 
4.8 Analyzing ferritin concentration in plasma 
For the quantitative determination of ferritin in plasma, we used the Mouse Ferritin ELISA kit 
(#80636) from Crystal Chem, Inc. 5 µl of thawed heparinized plasma was diluted to 1:40 with 
the diluent provided by the kit and used for the assay. The manufacturer instructions were 
thoroughly followed, and the absorbance was measured using BioTeck Epoch™ 2 Microplate 
Spectrophotometer at 450 nm and values at 630 nm were subtracted. All the samples were 
measured in duplicates. The concentration of ferritin was calculated by extrapolation of the 
mean absorbance for each sample to the standard curve which was calculated by 4-parameter 
logistic regression using a computer software.  
 
4.9. Non-heme iron measurement in tissue 
To analyze the amount of iron in tissue, we used a protocol for non-heme iron determination in 
tissue kindly provided by Bruno Galy and Sandro Altamura from the University of Heidelberg, 
which is a modification of the method described by Torrence and Bothwell.135 
We first dried the tissue at 45° for 3 days. Next, in order to achieve the non-heme iron 
solubilization, we weighted the dried tissue fragments and added tissue-specific volumes 
(Table 3) of freshly prepared TCA/HCL reagent (Table 4). We incubated the tissue at 65° for 
2 days on the thermomixer at 1000 rpm. After incubation, we centrifuged the samples at 5000 
rpm for 5 minutes to pellet the insoluble tissue remains.  
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Table 3. Volumes of TCA/HCL r and iron solution for non-heme iron measurement in tissue  
Tissue TCA/HCL per 
0.01g of tissue 
TCA/HCL for 
assay 
Volume for 
assay 
Liver 100 µl 20 µl 2 µl 
Spleen 900 µl 20 µl 1 µl 
Tumor 50 µl 20 µl 4 µl 
Kidney 100 µl 20 µl 2 µl 
 
To prepare the standard curve we diluted the standard iron solution Iron Standard for AAS, 
10.00 g/L Fe in nitric acid (#02583) from Sigma-Aldrich to 40 µg/ml in TCA/HCL reagent and 
different dilutions of the standard were prepared (Table 5). 20 µl of the blank (only HCL/TCA) 
and the standard dilutions were loaded in duplicates in a 96 wells plate. To measure the samples 
20 µl of TCA/HCL reagent was added to each swell and tissue specific sample volumes (Table 
3) were added in triplicates to the plate. To the blank, standard series and two of each of the 
triplicates 100 µl of the stain solution (Table 4) was added. To the third sample well, we added 
100 µl of the control solution (Table 4). The plate was incubated for at least 15 minutes at room 
temperature and absorbance was read by BioTeck Epoch™ 2 Microplate Spectrophotometer at 
535 nm against blank within 3 hours. Previously to the calculation of the results, the absorbance 
of the well containing sample plus the control solution was subtracted from the correspondent 
average of the absorbance of the wells containing the same sample and stain solution.  
 
Table 4. Reagents recipes for non-heme iron measurement in tissue 
Solutions  
TCA/HCL 25.2 ml H2O 
10.8 ml 37% HCL 
4 ml 100% TCA 
Stain solution 40 µl 10% BDA (bathophenanthroline disulfoxid acid) 
570.8 µl of 70% thioglycolate 
39.4 ml of 3 M sodium acetate 
Control 
solution 
570.8 µl of 70% thioglycolate 
39.4 ml of 3 M sodium acetate 
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Table 5. Iron standard curve preparation for non-heme iron measurement in tissue 
 
µl of 40 
µg/mL 
solution 
µl HCl/TCA Iron 
concentration 
(ng/µl) 
Iron (ng) in 20 
µl 
1 0 200 0 0 
2 1 199 0.2 4 
3 2 198 0.4 8 
4 5 195 1 20 
5 10 190 2 40 
6 20 180 4 80 
7 30 170 6 120 
8 40 160 8 160 
9 50 150 10 200 
10 60 140 12 240 
11 75 125 15 300 
12 100 100 20 400 
 
 
 
4.10 Bone marrow smears 
Bone marrow smears from tumor-bearing Trp53floxWapCre mice at end stage (maximal 
permitted tumor size) and tumor free control mice were obtained from the medullar cavity of 
femur using the paint brush technique.136 Slides were air-dried and stained with a Giemsa 
staining. The cells were morphologically evaluated and a differential count of the hematologic 
precursors was performed by light microscopy at 100x. 
 
 
4.11 Flow cytometry experiments 
Late erythropoiesis analysis in bone marrow and spleen of tumor-bearing 
Trp53floxWapCre mice. 
Cells from bone marrow and spleen from iron or saline treated or non-treated Trp53floxWapCre 
tumor-bearing mice at end stage and age-matched tumor free mice were harvested, stained and 
analyzed by flow cytometry following a protocol adopted from Chen et al.137 
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Bone marrow cells were flushed out from the medullar cavity of the two femurs and two tibias 
by using a 1 ml syringe attached to a 24 G needle with ice-cold RPMI cell culture medium 
enriched with 2.5 % FBS. Clumps were dispersed by gently pipetting with a 10 ml pipette. 
In order to obtain a single cell suspension, the spleen was strained by pouring it through a 40 
µm strainer using the barrel of a 2 ml syringe until only small portion of fibrous tissue remained 
on the strainer.  
Bone marrow and spleen cells were resuspended in a defined volume of staining buffer (PBS 
supplemented with 0.5% BSA and 0.1% sodium azide) and the concentration was evaluated by 
using a Neubauer chamber. 3x106 cells were diluted in 100 ml of staining buffer and Fc 
membrane receptors were blocked with 1 µl/106 cells of Purified anti-mouse CD16/32 Antibody 
(# 101302) from Biolegend for 15 minutes on ice. Cells were washed with 1 ml of staining 
buffer and centrifuged at 500 x g for 5 minutes at 4°C. 
Cells were stained by resuspending the cell pellet with the labeled-antibodies cocktail in a total 
volume of 100 µl of PBS:  1 µl FITC anti-mouse TER-119/Erythroid Cells Antibody (#16205) 
from Biolegend, 0.625 µl of APC-Cy™7 Rat Anti-Mouse CD45 (#561037) from BD 
Pharmingen™, 0.3125 µl APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody (#108423) 
from Biolegend, 0.625 µl APC Rat Anti-Mouse CD44 Clone IM7 (RUO) (#561862) from BD 
Pharmingen™ and 1 µl of Zombie Yellow™ Fixable Viability Kit  (#423103) from Biolegend. 
Cells were incubated with the labeled-antibodies cocktail for 30 minutes on ice in the dark. 
After incubation, cells were washed 3 times with 1 ml of staining buffer and centrifuged at 500 
x g for 5 minutes at 4°. Then, cells were resuspended in 0.2 ml of staining buffer and filtered 
with a 40 µm strainer. Cell suspensions were kept at 4° in the dark and analyzed within the next 
2 hours with Cytoflex S Flow Cytometer from Beckman Coulter Life Sciences.  
Results were analyzed with FlowJo software (Tree Star, Ashland, OR, USA). The gating 
strategy showed in Figure 5 was applied to all bone marrow and spleen samples. In detail, 
events considered debris were discarded (Fig. 5A). Events placed on the middle diagonal of the 
FSC-H versus FSC-A plot were considered single cells and therefore included in the analysis 
(Fig. 5B). For all dyes, the correspondent FMO (fluorescence minus one) control was used to 
define the gates. Zombie YellowTM is an amine-reactive fluorescent dye that is non-permeant 
to live cells but permeant to the cells with compromised membranes; therefore, only unstained 
cells were selected (Fig. 5C). Ter119 is an erythroid-specific glycophorin expressed in late 
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erythroid precursors (from proerythroblasts to mature erythrocyte). All FITC-Ter119+ cells 
were considered as late erythroid precursors.  
As described by Chen et al.,138 with maturation, erythroid precursors show progressive decrease 
of CD44 surface expression with decreased cell size. Therefore all Ter119+ cells were displayed 
in a APC-CD44 versus FSC-A plot allowing to differentiate 5 different clusters corresponding 
to the different stages of the maturation (Fig. 5E): proerythroblasts (I), basophilic erythroblasts 
(II), polychromatic erythroblasts (III), orthochromatic erythroblasts and reticulocytes (IV) and 
mature erythrocytes (V).139 CD45/GR1+ cells where considered leukocyte precursors.  
 
Figure 5 
  
 
 
Fig 5: Flow cytometric analysis of late erythroid maturation in bone marrow and spleen in tumor-bearing 
Trp53floxWapCre mice 
Shown are representative images of the gated plots and the gating strategy used for the late erythroid maturation assessment in 
bone marrow and spleen of tumor free and tumor-bearing Trp53floxWapCre mice. (A) Events considered cells were gated in a 
forward scatter (FSC-Area; cell size) vs. side-scatter (SSC-Area, cell complexity) plot, (B) single cell gating in FSC-Area vs. 
FSC-Height plot, (C) live cell gating by Zombie Yellow (stains dead cells) vs. SSC-Area plot, (D) Ter119+ (late erythroid 
precursors) gating on living cells in Ter119 vs SSC-Area plot, (E) different clusters were identified in FSC-Area vs. CD44 plot 
and based on the decreasing cell size and CD44 membrane concentration on the erythroid cells with maturation, the different 
stages of the late erythroid maturation were gated: proerythroblasts (I), basophilic erythroblasts (II), polychromatic 
erythroblasts (III), orthochromatic erythroblasts and reticulocytes (IV) and mature erythrocytes (V); (F) CD45/GR1+ cells 
(leukocyte precursors) gating in CD45/GR1 vs SSC-Area plot. 
 
 
A C B 
D E F 
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Early erythropoiesis analysis in bone marrow of tumor-bearing 
Trp53floxWapCre mice. 
Bone marrow cells from tumor-bearing Trp53floxWapCre mice at end stage and age matched 
tumor free mice harvested, stained and analyzed by flow cytometry following the protocol 
defined by Pronk et al.140 
Bone marrow cells were passed through 23 G needles to get single-cell suspensions. Two 
femurs per mouse were used for hematologic stem cells (HSC) analysis, and 2 femurs and 2 
tibiae per mouse were used for sorting. For surface staining, cells were incubated with c-kit 
(A780, 2B8; eBioscience), Sca1 (PE-Cy5 or PE-Cy7 or PE-Cy5.5, D7; eBioscience), CD34 
(FITC, RAM34; eBioscience), CD135 (PE or PE-Cy5, A2F10; eBioscience), CD48 (APC, 
HM48-1; eBioscience), CD150 (PE-Cy7, TC15-12F12.2; BioLegend), CD105 (PE, 12-1051-
82, ThermoFisher) and CD41 (FITC, 11-0411-82; ThermoFisher) for 55 minutes. Lineage-
positive cells were excluded using a cocktail of biotinylated antibodies and staining with 
streptavidin (SA; eF450; eBioscience). The lineage cocktail included CD3 (145-2C11; 
eBioscience), CD19 (eBio1D3; eBioscience), NK1.1 (PK136; eBioscience), Ter119 (Terr119; 
eBioscience), CD11b (M1/70; eBioscience), Gr1 (RB6-8C5; eBioscience), and B220 (RA3-
6B2; eBioscience). A total of 3x106 cells per mouse were acquired. Fluorescence-activated cell 
sorting (FACS) analysis was performed on LSRII (Becton Dickinson), and sorting was done 
on Aria II (Becton Dickinson). Cell numbers were counted on MACS quant. Data were 
analyzed with DIVA (Becton Dickinson), MACS quantify (Miltenyi), or FlowJo (Tree Star, 
Ashland, OR, USA). The used gating strategy was adopted from Pronk et al.140 and is shown in 
Figure 6.  In detail, cells not stained by the lineage cocktail where selected. C-kit+/ SCA-1+ 
cells were positively gated and from those, events CD48-/CD150+ were considered 
hematopoietic stem cells (HSC), whereas events CD48+/CD150- expression were considered 
multipotent progenitors (MPP).  
Additionally, c-kit+/SCA1- events were selected. CD150+/CD41+ cells were considered Mkp 
(megakaryocyte precursors) and CD41- events were selected and plotted again as CD16_32 
versus CD150. All events CD16_32- were selected and plotted as CD105 vs CD150. In this plot 
the rest of early precursors populations were defined: CD105-/ CD150- were considered as pre-
granulocyte-monocyte lineage cells (Pre-GM), CD105-/CD150+ pre-megakaryocyte-
erythrocyte progenitors (pre-MgE), CD105+/ CD150+ pre-colony forming units erythrocyte 
(pre-CFU) and CD150-/ CD105+ were considered colony forming units erythrocyte (CFUe). 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Flow cytometric analysis of early erythropoiesis in bone marrow of tumor-bearing Trp53floxWapCre mice 
Shown are representative images of the gated plots and the gating strategy used for the early hematopoietic precursors 
assessment in bone marrow. Lin- cells were selected. C-kit+/ SCA-1+ cells were selected and from those, events CD48-/CD150+ 
were considered hematopoietic stem cells (HSC), whereas events CD48+/CD150- expression were considered multipotent 
progenitors (MPP). From c-kit+/SCA1- events, CD150+/CD41+ cells were considered Mkp (megakaryocyte precursors) and 
CD41- events were selected and plotted as CD16_32 versus CD150. Events CD16_32- were plotted as CD105 vs CD150. 
CD105-/ CD150- were considered as pre-granulocyte-monocyte lineage cells (Pre-GM), CD105-/CD150+ pre-megakaryocyte-
erythrocyte progenitors (pre-MgE), CD105+/ CD150+ pre-colony forming units erythrocyte (pre-CFU) and CD150-/ CD105+ 
were considered colony forming units erythrocyte (CFUe). 
 
 
4.12 Statistics  
All statistics were performed in GraphPad Prism6 (GraphPad Software, San Diego, US). Data 
distribution was analyzed with the Kolmogorov-Smirnov test.141 To compare 2 independent 
groups, we used either an Unpaired Student t-test for parametric distributed data or a Man-
Whitney test for non-parametric distributed data.141 To compare three or more independent 
groups with just one independent variable, we used either One-way-ANOVA with a Dunnett’s 
Multiple Comparison Test for parametric data or a Kruskal-Wallis test, with a Dunn’s Multiple 
Comparison Test for non-parametric data. Correlation analyses were performed with linear 
regression analysis.141 A p-value of ≤ 0.05 was considered significant.142 The respective 
statistical tests are indicated in the figure legends.  
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5. Results 
 
5.1 Trp53floxWapCre mice develop breast cancer associated with 
Epo-resistant anemia 
Trp53floxWapCre mice developed subcutaneous mammary tumors between 20 and 36 weeks of 
age. Typically, the tumors were mammary carcinomas associated with large necrotic areas with 
diffuse and severe neutrophilic inflammation (Fig. S1). Between 18 to 43 days after the tumor 
onset, tumor-bearing mice reached experimental termination criteria (defined as end stage, ES), 
which were defined by a single tumor volume of 2 cm3 or by a total volume of 3 cm3 in mice 
with multiple tumors. 
Tumor-bearing Trp53floxWapCre mice developed AC. Hematocrit and hemoglobin levels were 
reduced from average 42.39% or 13.13 g/dl respectively in tumor free to 35.71% or 10.76 g/dl 
tumor-bearing Trp53floxWapCre mice at end stage (pHct=0.0001 and pHb=0.0001) (Fig. 7A, B). 
The treatment with subcutaneous injection of 1000 U/kg Epo three times per week from tumor 
onset was not able to palliate the anemia (Fig. 7C) but did also not increase tumor growth in 
our mouse model (Fig. 7D). 
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Fig.7 Epo resistant anemia in tumor-bearing Trp53floxWapCre mice 
Shown is (A) hematocrit and (B) hemoglobin of age-matched tumor free (TF, white box) and tumor-bearing Trp53floxWapCre 
mice after reaching termination criteria (defined as end stage; ES, red box). (C) Shown is the hematocrit of tumor-bearing 
Trp53floxWapCre mice at end stage subcutaneously injected with either with 1000 U/kg Epo (Epo, purple box) or saline (NaCl, 
green box) 3 times a week. The black dotted line indicates the median of the untreated tumor free Trp53floxWapCre mice. (D) 
Kaplan-Meier survival curve of tumor-bearing Trp53floxWapCre mice treated with 1000 U/kg Epo (purple line) or saline (NaCl, 
black line) 3 times per week (n=12-14). Of note, the survival curve does not indicate the time when the mice died from cancer 
but the time point the experiment was terminated because of reaching maximal permitted tumor size (of 2 cm3 for single or a 
total of 3 cm3 for multiple tumors) A, B, C: Data are shown as box plot with min to max whiskers and an Unpaired Student t-
test was performed; ****p<0.0001 (n=9-30). 
 
 
 5.2 Trp53floxWapCre mice develop AC at advanced stages of 
tumorigenesis 
To assess if AC in tumor-bearing Trp53floxWapCre mice occurs early or late during tumor 
progression, we analyzed hematological parameters at different stages of the disease from day 
0 (the day of tumor diagnosis) to day 7 and 15 after tumor diagnosis as well as at end stage (ES) 
(Fig. 8 and Table 6). We observed a trend of reduced hematocrit levels in tumor-bearing mice 
immediately after tumor onset (day 0), but statistical differences (p=0.0008) were only observed 
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between tumor free (41.67%) and tumor-bearing mice at end stage (34.83%) (Fig. 8A). 
Hemoglobin levels were neither reduced on day 0 nor in more than 50% of tumor-bearing mice 
on day 15. However, a few mice started to develop anemia especially mice that displayed 
already large tumors on day 15 (Fig. 8 B). However, end stage tumor-bearing Trp53floxWapCre 
mice showed clearly lower hemoglobin levels (10.85 g/dl) than tumor free mice (13.82 g/dl) 
(p=0.0088). The reduced hemoglobin levels in tumor-bearing mice correlated with a decreased 
erythrocyte number, an increased mean corpuscular volume (MCV) and a decreased mean 
corpuscular hemoglobin concentration (MCHC) (Table 6). The reticulocyte count was not 
changed in any of the tumor stages analyzed, indicating that tumor-bearing animals at advanced 
stages of the disease present a no-regenerative macrocytic anemia. 
 
Fig.8 Time course of anemia of cancer in Trp53floxWapCre mice.  
Shown is (A) hematocrit, (B) hemoglobin and (C) renal Epo mRNA levels of tumor free (TF, white boxes) and tumor-bearing 
Trp53floxWapCre mice (red boxes) at different stages of the disease: immediately after tumor diagnosis (0 d), 7 days (7 d) and 
15 days after de diagnosis (15 d) or when mice reached experimental termination criteria by maximum permitted tumor size 
(end stage, ES). (D) Epo concentration in plasma of tumor free (TF, white box) and tumor-bearing Trp53floxWapCre mice (red 
boxes) at end stage (ES) was measured by ELISA. Data are shown as box plot with min to max whiskers and One-way ANOVA 
(panel A and C) with a Dunnett’s Multiple Comparison post hoc test., a Mann Whitney test (panel D) and a Kruskal-Wallis 
with a Dunn’s Multiple Comparison post hoc test (panel B) was performed; (n=4-13); *p<0.05; ***p<0.001. 
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To analyze if the Epo production increased in response to AC, we measured Epo mRNA levels 
in the kidney (Fig. 8C) immediately after tumor diagnosis (day 0) and at early stages of tumor 
progression (day 7), but no differential Epo mRNA expression was observed in these time 
points. However, Epo mRNA levels in mice with large tumors, i.e. end stage (ES) were 2.02-
fold higher than in tumor free mice. Additionally, Epo plasma levels increased in tumor-bearing 
mice 4.34-fold but did not reach significance (p-value 0.056) (Fig. 8D).  
 
Table 6: Hematological parameters of tumor free and tumor-beating Trp53floxWaypCre mice at different 
timepoints after tumor onset. 
 
Parameter TF 0d 15d ES Statistical test 
Erythrocyte count (106/μl) 9.772 ± 0.32 9.495 ± 0.37 9.128 ± 0.81 7.697 ± 
0.62**** 
1w ANOVA 
RDW (%) 23.02 ± 0.74 23 ± 0.94 22.52 ± 0.36 22.08 ± 1.2 KW 
MCV (fl) 42.67 ± 0.52 42 ± 1.15 43 ± 0.71 45.17 ± 1.17** KW 
MCH (pg) 14 ± 0.0 14.75 ± 0.50 14.2 ± 0.84 14 ± 0.63 KW 
MCHC (g/dL) 33.17 ± 0.75 34.75 ± 0.50 32.8 ± 1.64 31.33 ± 1.03** KW 
Reticulocytes (%) 6.308 ± 2.00 8.24 ± 0.17 5.982 ± 1.78 9.065 ± 0.79 KW 
Reticulocytes (10E6/μl) 0.6178 ± 0.20 0.7608 ± 0.04 0.5358 ± 0.11 0.7114 ± 0.09 KW 
Values are presented as mean ± standard deviation; RDW: red cell distribution width; MCV: mean corpuscular volume; MCH: 
mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration. TF: tumor free control mice; 0d: mice at 
day of tumor diagnosis; 15d: mice at 15 days after tumor diagnosis; ES: tumor-bearing mice at end stage (when they reach 
termination criteria, i.e. maximal permitted tumor size). 1w ANOVA: One-way ANOVA with Dunnett’s Multiple Comparison 
Test; KW: Kruskal-Wallis test, Dunn’s Multiple Comparison Test (n=4-6); ****p<0.0001, **p>0.01.  
 
Spleen weight of tumor-bearing mice increased (splenomegaly) during disease progression and 
was 2.44-fold higher at end stage than in tumor free mice (Fig. 9A).  This marked increase in 
the spleen size together with the histological spleen analyses of tumor-bearing mice at end stage 
(Fig. 9C, D) suggested that stress erythropoiesis occurred in the spleen.  
Similar to spleen, the liver weight was larger (hepatomegaly) in tumor-bearing mice at late 
stages than in tumor free mice (Fig. 9B), but no alteration of the hepatocyte morphology, 
number of inflammatory cells or focus of extramedullary erythropoiesis could be histologically 
observed (Fig. 9 E, F). The increased liver weight might have been a result of increased cellular 
hepatocyte replication (Fig. S2) because tumor-bearing mice displayed more Ki67 positive cells 
in the liver than tumor free mice.  
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Fig.9 Organ weight and histological changes in spleen and liver of tumor-bearing Trp53floxWapCre.  
Shown are (A) spleen weight and (B) liver weight normalized to the body weight of tumor free (TF, white boxes) and tumor-
bearing Trp53floxWapCre mice (red boxes) at different stages of the disease: immediately after tumor diagnosis (0d), 7 days 
after tumor diagnosis (7d) or when mice reached experimental termination criteria by maximum permitted tumor size (end 
stage, ES). Data are shown as box plot with min to max whiskers and One-way ANOVA (panel A) with a Dunnett’s Multiple 
Comparison post hoc test. And a Kruskal-Wallis with a Dunn’s Multiple Comparison post hoc test (panel B) was performed 
(n=10-13); ****p<0.00001; ***p<0.001; Representative H&E stained tissue sections of spleen from (C) tumor free mice and 
(D) tumor-bearing mice. Scale bar 1 mm. Representative sections of liver from (E) tumor free mice and (F) tumor-bearing 
mice. Scale bar 100 µm. 
 
To analyze the general health status of the mice and verify that neither kidney nor liver 
pathologies contributed to the anemia pathogenesis in Trp53floxWapCre mice, we analyzed 
clinical markers (specified in Table 7) in plasma of tumor free and tumor-bearing mice. We 
observed no differences in the creatinine and a slight decrease in the urea plasma concentration 
from 36.18 to 31.62 mg/dl (p=0.035) between tumor free and tumor-bearing (end stage) mice, 
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indicating that kidney function was not impaired. Hepatic aspartate (AST) and alanine 
transaminases (ALT) levels were decreased from 496.7 to 173.4 IU/L, however only significant 
at p=0.102, and from 39.57 to 21.57 IU/L (p=0.035), respectively. Additionally, alkaline 
phosphatase (AP) decreased from 89.0 in tumor free to 30.5 IU/L levels in tumor-bearing mice 
(p=0.0001) and total protein increased from 40.43 in tumor free to 50.00 g/l in tumor-bearing 
mice (p=0.0058). Glucose, bilirubin, cholesterol and triglyceride did not change in tumor-
bearing mice, suggesting that both liver and kidney function were not altered.  
 
Table 7: Plasma biochemistry of tumor free and tumor-bearing (end stage, ES) Trp53floxWapCre mice.  
Values presented as mean ± standard deviation; TF: tumor free control mice; ES: tumor-bearing mice at end stage (when they 
reach termination criteria). (n=7) *p<0.05; **p<0.01; ****p<0,0001.  
 
5.3 Trp53floxWapCre mice develop a marked inflammatory 
response during tumor progression 
Because AC is usually associated with inflammation, we investigated the number of 
inflammatory cells in peripheral blood of tumor free and tumor-bearing mice at different stages 
of the disease (Fig. 10). The overall leukocyte count was 2.29-fold increased (p<0.0001) in end 
stage (ES) tumor-bearing mice but not at earlier time points (Fig. 10A) and it is mainly a 
consequence of the approximately 10-fold higher numbers of neutrophils (Fig. 10B) and 
Parameter TF ES Statistical test 
Creatinine (mg/dl) <0.17 ± 0.0 <0.17 ± 0.0  
Urea (mg/dl) 36.18 ± 2.906 31.62 ± 4.155* Unpaired t test 
Aspartate transaminase (AST) IU/l 496.7 ± 473.4 173.4 ± 97.57 Unpaired t test 
Alanine transaminase (ALT) IU/l 39.57 ± 18.86 21.57 ± 6.705* Unpaired t test 
Alkaline Phosphatase (AP) (IU/l) 89.00 ± 7.321 30.50 ± 11.61**** Unpaired t test 
Total protein (g/l) 40.43 ± 1.718 50.00 ± 7.371** Unpaired t test 
Glucose (mg/dl) 186.2 ± 28.59 163.4 ± 30.84 Unpaired t test 
Bilirubin (mg/dl) <0.1843 ± 0.058 <0.24 ± 0.1261 Mann Whitney test 
Cholesterol (mg/dl) 106.3 ± 8.025 116.6 ± 42.14 Mann Whitney test 
Triglycerides (mg/dl) 191.9 ± 49.27 202.2 ± 182.7 Mann Whitney test 
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monocytes (Fig. 10C). In contrast, the number of lymphocytes (Fig. 10D) and eosinophils (Fig. 
10E) did not differ between tumor free and tumor-bearing mice. Basophils were decreased at 
end stage in tumor-bearing mice (p=0.067) (Fig. 10F). These results indicate a marked cellular 
inflammatory response in peripheral blood of tumor-bearing animals at end stage, which 
predominantly involved neutrophils and monocytes. 
Besides the cellular response, we observed on molecular level that interleukin-6 (IL-6), an 
inflammatory cytokine with a principal role in anemia of inflammation pathogenesis, was 
increased.  IL-6 mRNA expression in tumor tissue of tumor-bearing mice at end stage was 
approximately 5 times higher than in normal mammary tissue of tumor-free Trp53floxWpCre 
mice (Fig. 11A). In addition to tumor IL-6 mRNA levels, we measured IL-6 protein 
concentration in plasma of tumor free and tumor-bearing mice immediately and 15 days after 
tumor onset as well as at end stage (Fig. 11B). We observed increased IL-6 plasma levels 
already 15 days after tumor onset, but differences were only significant (p=0.0041) at the end 
stage when IL-6 levels were approximately 50 times higher than in tumor free mice. To confirm 
that tumor-bearing mice responded to the elevated IL-6 levels we analyzed the liver mRNA 
expression levels of serum amyloid-A1 (SAA-1), a liver marker of IL-6 activity. Correlating 
with the IL-6 serum levels, we observed an increased SAA-1 mRNA expression with disease 
progression, which already reached significance 7 days after the tumor diagnosis (p=0.05) and 
even became 158.48 times higher than tumor free mice at end stage (p<0.0001) (Fig. 11C).  
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Fig. 10: Differential leukocyte count in peripheral blood of tumor free and tumor-bearing Trp53floxWapCre mice. 
Shown are leukocytes (A), neutrophils (B), monocytes (C), lymphocytes (D), eosinophils (E) and basophils (F) cell count in 
peripheral blood of tumor free mice (TF, white boxes) and tumor-bearing mice at different stages of the disease: immediately 
after tumor diagnosis (0 d), 15 days after tumor diagnosis (15 d) and at end stage (ES), when tumors reached the maximal 
permitted size and the experiment was terminated. Data are shown as box plot with min to max whiskers and a One-way 
ANOVA with a Dunnett’s Multiple Comparison post hoc test (panel A, E and F) or Kruskal-Wallis with a Dunn’s Multiple 
Comparison post hoc test (panel B, C and D) was performed; (n=4-6); *p<0.05, **p<0.01, ***p<0.001. 
 
 
Leukocytes count
TF 0d 15
d ES
0
10
20
30
Le
uk
oc
yt
es
(x
10
3 /µ
l) ***
Monocytes count
TF 0d 15
d ES
0
1
2
3
M
on
oc
yt
es
 (x
10
3 /µ
l)
**
Eosinophils count
Eo
si
no
ph
ils
 (x
10
3 /µ
l)
TF 0d 15
d ES
0.0
0.1
0.2
0.3
0.4
0.5
Neutrophils count
TF 0d 15
d ES
0
5
10
15
20
N
eu
tr
op
hi
ls
 (x
10
3 /µ
l) *
Lymphocyte count
TF 0d 15
d ES
0
10
20
30
Ly
m
ph
oc
yt
es
 (x
10
3 /µ
l)
Basophils count
TF 0d 15
d ES
-0.02
0.00
0.02
0.04
0.06
0.08
B
as
op
hi
ls
 (x
10
3 /µ
l)
*
Figure 10
A B
C D
E F
   
 
42 
Moreover, we analyzed the expression in tumor tissue of some proinflammatory cytokines 
involved in the regulation of the erythropoiesis and compared them with healthy mammary 
tissue of tumor-free mice. We found that interleukine-1b (IL-1b) expression was 5.7-fold 
(p<0.0001) increased in tumor tissue (Fig. 11D), but conversely, the expression of tumor 
necrosis factor alpha (TNF-a) was reduced by 10.3-fold (p=0.0002) in tumor tissue (Fig. 11E). 
These results show that some proinflammatory cytokines that might be involved in the AC 
pathogenesis are secreted by the tumor or the inflammatory cells present in the tumor tissue. 
 
Fig. 11: Induced IL-6 levels and other cytokines expression in tumor-bearing Trp53floxWapCre mice. 
Shown is (A) interleukin-6 (IL-6) mRNA levels in normal mammary tissue of tumor free mice (TF) and in tumor tissue of 
tumor-bearing-mice at end stage (ES) and (B) interleukin-6 (IL-6)  plasma levels as well as (C) liver serum amyloid-A (SAA-
1) mRNA expression levels of tumor free (TF, white boxes) and tumor-bearing-mice (red boxes) at different stages of the 
disease: immediately after tumor diagnosis (0 d), 15 days after tumor diagnosis (15 d) and at end stage (ES), when tumors 
reached the maximal permitted size and the experiment was terminated. (D) Interleukin-1b (IL-1b) and tumor necrosis alpha 
(TNFa) relative mRNA expression in healthy mammary tissue of tumor free mice (TF, white boxes) and in tumor tissue of 
tumor-bearing mice at end stage (ES, red boxes). Data are shown as box plot with min to max whiskers and either an Unpaired 
Student t-test (panel A, D, E) or a Kruskal-Wallis with a Dunn’s Multiple Comparison post hoc test (panel B and C) was 
performed (n=3-11). *p<0.05; **p<0.01; ****p<0.0001, ***p<0.001 
 
5.4 Reduced iron availability in tumor-bearing Trp53floxWapCre 
mice 
 
Alteration of iron availability is one the most frequent cause of anemia of inflammation. 
Because the severe inflammation and Epo unresponsiveness in tumor-bearing Trp53floxWapCre 
mice, we analyzed if  iron status was altered. Both, iron concentration and transferrin saturation 
were decreased by 19.01% (p=0,0049) and 54.7% (p<0.0001), respectively, in the serum of 
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tumor-bearing mice when compared to tumor free mice (Fig. 12A, B). Together with the 
unsaturated iron binding capacity and the total iron binding capacity that increased by 174.89% 
(p<0.0001) and 70.24% (p<0.0001), respectively (Fig. 12C, D), these data suggested that 
tumor-bearing mice suffered reduced iron availability. Plasma ferritin concentration reflects the 
amount of stored iron in the body and was 2.25-fold (p<0.0001) lower in tumor-bearing 
Trp53floxWapCre mice that reached maximal permitted tumor size (end stage ES) than in tumor 
free (Fig. 12E). However, the ferritin plasma concentration was already 1.5-fold lower 
(p<0.0001) on the day of the tumor diagnosis (day 0) and 1.98-fold lower (p=0.01) 7 days after 
tumor diagnosis than in tumor free mice. Iron concentration in liver and spleen was 1.3-fold 
(p=0.0104) and 3.4-fold (p<0.0001) lower, respectively, in tumor-bearing than in tumor free 
mice (Fig. 12F,G), but the total amount of liver stored iron was 1.56-fold (p<0.0001) higher in 
tumor-bearing mice than in tumor free mice and it was no different in the spleen of because of 
the increased liver and spleen size (shown in Fig. 9)  in tumor-bearing animals  (Fig. 12H, I).  
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Fig. 12: Iron status in tumorbearing Trp53floxWapCre mice 
Shown are (A) iron concentration, (B) transferrin saturation, (C) unsaturated iron binding capacity and (D) total iron binding 
capacity in plasma of tumor-bearing Trp53floxWapCre mice at end stage, i.e. reaching maximal permitted tumor size (ES, red 
boxes) and tumor free control mice (TF, white boxes). (E) The ferritin concentration was measured by ELISA in plasma of 
tumor free (TF, white boxes) and tumor bearing-mice (red boxes) at different stages of the disease: immediately after tumor 
diagnosis (0d), 7 days after tumor diagnosis (7d) and at end stage, when maximal tumor size was reached (ES). (F) The non-
heme iron concentration in dried liver, (G) the non-heme iron concentration in dried spleen, (H) the total non-heme iron content 
in the liver and (I) the total non-heme iron content spleen. Data are shown as box plot with min to max whiskers and either an 
Unpaired Student t-test (panel A, C, D, F, G, H, I), a Mann Whitney test (panel B) or a One-way ANOVA with a Dunn’s 
Multiple Comparison post hoc test was performed (n=6-22). *p<0.05; **p<0.01; ****p<0.0001.  
 
 
A Perl’s DAB enhanced stain for tissue iron distribution confirmed that iron in liver and spleen 
of tumor-bearing mice was decreased (Fig. 13A, B, C, D). Spleen iron was mainly stored in the 
macrophages of the red pulp of tumor free (Fig. 7A) and tumor-bearing mice (Fig. 13B), 
however, to a lesser extent in tumor-bearing mice. Liver iron of tumor free mice was stored in 
the Kupffer cells, but also distributed in the cytoplasm of the hepatocytes. However, reduced 
iron staining in tumor-bearing mice was mainly observed in the hepatocytes but less in Kupffer 
cells (Fig. 13C, D). Likewise, reduced iron staining in the bone marrow of tumor-bearing 
animals was also observed (Fig. 13E, F). Kidney iron was mainly detected at the proximal 
tubules (Fig. 13G, H) but tumor-bearing mice animals showed a less intense staining than 
tumor free mice, suggesting that tumor-bearing mice might filter less iron. Iron in tumor tissue 
was unequally distributed (Fig. 13I). Only a few tumor areas showed a detectable iron 
accumulation, mainly inside the inflammatory cells, such as macrophages, but also in the 
cytoplasm of cancer cells 
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Fig 13. Iron accumulation and distribution in spleen, liver, bone marrow, kidney and tumor of Trp53floxWapCre mice. 
Tissue sections were stained with DAB-enhanced Perls' to stain (A, B) spleen, (C, D) liver, (E, F) bone marrow, (G, H) kidney 
and (I) tumor tissue. Shown are representative images of tumor free control mice (left panels) and tumor-bearing 
Trp53floxWapCre mice, at end stage, i.e. when they reached maximal permitted tumor size (right panels). Scale bar 100 or 250 
µm. 
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5.5 Altered iron metabolism in tumor-bearing Trp53floxWapCre 
mice 
 
Because of the reduced iron availability in tumor-bearing mice we analyzed different genes 
related to iron metabolism in the liver in order to investigate the mechanisms leading to the 
decrease of iron in blood. We analyzed mRNA levels of hepcidin (Hamp 1 and Hamp 2), which 
is the IL-6 inducible major regulator of iron homeostasis. Despite the marked inflammatory 
response in tumor-bearing mice, Hamp1 mRNA levels (Fig. 14 A) (and Hamp2; data not 
shown) did not increase but remained constant in early cancer progression phases of tumor-
bearing mice and decreased 2.4-fold (p<0.001) at late tumor progression stages. Gene 
expression of ferroportin (Fpn), the only known iron exporter, was not differentially regulated 
(Fig. 14B) but it might have been regulated post-transcriptionally and post-translationally in 
tumor-bearing Trp53floxWapCe mice. Fth1 encoding for the heavy subunit of ferritin, the iron 
storage protein, was decreased 1.32-fold (p<0.01) in tumor-bearing mice at end stage, but not 
early during the disease progression (Fig. 8C). In contrast, mRNA expression of the serum iron 
carrier transferrin (Trf) increased 2.44-fold (p<0.0001) in late tumor progression stages but not 
in early stages (Fig. 14D). Bone morphogenic protein-6 (BMP-6) responds to varying iron 
storage levels and increases hepcidin expression through the BMP-SMAD pathway when iron 
levels in tissue are high33. However, BMP-6 mRNA expression did not increase in tumor-
bearing mice but was reduced 5.98-fold (p<0,001) in late stages of tumor progression (Fig. 
14E); and gene expression of Hemojuvelin (Hfe2), a BMP-6 coreceptor, was not differentially 
regulated (Fig. 14F).  Homeostatic iron regulator (Hfe) induces hepcidin expression when 
serum iron levels are high, but liver mRNA levels of Hfe (Fig. 14G) as well as both transferrin 
receptors 1 (TfR1) and 2 (TfR2) were not differentially regulated (Fig 14H, I). Taken together, 
we observed differential mRNA levels of genes involved in iron homeostasis, transport and 
storage, indicating that tumor inflammation impacts on iron metabolism. 
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Fig. 14: Liver mRNA levels of genes involved in iron metabolism in tumor-bearing Trp53floxWapCre mice. 
Shown are (A) hepcidin-1 (Hamp-1), (B) ferroportin (Fpn), (C) ferritin heavy chain (Fth1), (D) transferrin (Trf), (E) bone 
morphogenic protein 6 (BMP-6), (F) hemojuvelin (Hfe2), (G) homeostatic iron regulator (Hfe), (H)  transferrin recepror-1 
(TfR-1) and (I) transferrin receptor-2 (TfR-2) 2 relative mRNA levels in the liver of tumor free mice (TF, white boxes) and 
tumor-bearing (red boxes) Trp53floxWapCre mice at different stages of tumor progression: immediately after tumor diagnosis 
(0d), 7 days after tumor diagnosis (7d) and at end stage (ES, when maximal permitted tumor size was reached). Data are shown 
as box plot with min to max whiskers and either a one-way ANOVA with Dunnett’s Multiple Comparison post hoc test (panel 
A, B, C, D, G), a Kruskal-Wallis with a Dunn’s pot hoc test (panel E) or an unpaired student`s t-test (panel F, H, I) was 
performed (n=5-11); ***p<0.001, **p<0.05; ****p<0.0001.  
  
Additionally, we analyzed the mRNA levels of some genes related with iron metabolism in 
bone marrow and spleen. The genes expressed mainly on the erythroid precursors were 
normalized to glycophorin-1(Gypa), a marker for erythroid precursors.143  Erythroferrone (Erfe) 
was opposite regulated in bone marrow than in spleen. In bone marrow the expression was 
increased 17.45-fold (p=0.0004) while in spleen was reduced 4.58-fold (p=0.0021) (Fig. 15A). 
We found no differences on the Epo receptor (EpoR) expression in bone marrow whereas in 
spleen the expression in tumor-bearing animals was reduced 1.78-fold (p=0.048) (Fig. 15B). 
Regarding hemoglobin alpha and beta chains, only a small reduction of 1.31-fold (p=0.0173) 
in bone marrow alpha chain expression level was found (Fig. 15C, D). Transferrin receptor 1 
(TfR1) expression was increased in bone marrow 2.15-fold (p=0.0096) and spleen 1.33-fold 
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(p=0.0236) of tumor-bearing mice (Fig. 15E), while transferrin receptor-2 expression (TfR2) 
was not modified (Fig. 15F).  
 
 
Fig. 15: Bone marrow and spleen mRNA levels of genes related with iron metabolism in tumor-bearing 
Trp53floxWapCre mice. 
Shown are (A) erythroferrone (Erfe); (B) Epo receptor (EpoR), (C) hemoglobin alpha chain (Hba); (D)   hemoglobin beta 
chain (Hbb); (E) transferrin recepror-1 (TfR-1); (F) transferrin receptor-2 (TfR-2) relative mRNA levels normalized to 
glycophorin-1 (Gypa) in bone marrow and spleen of tumor free mice (TF, white boxes) and tumor-bearing at end stage (ES, 
red boxes). Data are shown as box plot with min to max whiskers and either an Unpaired Student`s t-test (panel A, B, E, F) or 
a Mann Whitney test (panel C, D) was performed (n=4-6). *p<0.05; **p<0.01; ***p<0.001. 
 
5.6 Tumors of Trp53floxWapCre mice do not cause anemia when 
transplanted into immunocompromised Foxn1nu mice 
 
To further verify that inflammation is the driving force in AC in Trp53floxWapCre mice, we 
implanted tumors harvested from Trp53floxWapCre mice subcutaneously into 
immunocompromised Foxn1nu mice. Similar to the Trp53floxWapCre mouse model, a tumor 
size of 2 cm3 was the experiment termination criteria, which was reached within 29 and 49 
days. However, 3 out of 5 tumor-bearing nude mice started to develop skin ulceration at the 
tumor site and the experiment was prematurely terminated. We observed no clear differences 
in hematocrit and hemoglobin levels between tumor implanted and sham operated nude mice 
(Fig. 16A, B). Additionally, neither spleen nor liver weight differed between tumor-bearing 
and tumor free mice (Fig. 16C, D), however a trend of increased spleen size in tumor-bearing 
mice was noted. Similarly, only a trend of reduced serum iron concentration and transferrin 
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saturation in tumor-bearing animals was observed (Fig. 16E, F) whereas unsaturated and total 
iron binding capacity did not differ (Fig. 16G, H). 
 
  
Fig 16: Hematology and iron parameters in immunocompromised Foxn1nu mice after the transplantation of tumors of 
Trp53floxWapCre mice 
Shown is (A) hematocrit, (B) hemoglobin, (C) spleen weight as well as (D) liver weight normalized to body weight, (E) plasma 
iron concentration, (F) transferrin saturation, (G) unsaturated iron binding capacity and (H) total iron binding capacity of 
immunocompromised Foxn1nu mice implanted with tumors of Trp53floxWapCre mice (TB) or sham operated (TF). Data are 
shown as box plot with min to max whiskers and an Unpaired Student`s t-test for all panels (except panel B, Mann Whitney 
test) was performed (n=5). 
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50 
transferrin.  To analyze if iron supplementation restores normal blood levels in anemic, tumor-
bearing Trp53floxWapCre mice, we treated mice with a single intravenous injection of 13.3 
mg/kg ferric carboxymaltose (Ferinject®) or saline on the day of tumor diagnosis. Iron 
supplementation did neither accelerate nor delay the time until mice reached the maximal tumor 
volume (Fig. 17A) and no differences in hematocrit, hemoglobin, iron parameters in serum or 
iron content in liver, spleen or tumor were found between iron treated or saline injected groups 
at end stage (Fig. 17B-L). We repeated the experiment with a higher dose of ferric 
carboxymaltose of 20 mg/kg and sampled plasma and tissue 15 days after the injection in all 
mice to exclude i) that the administrated iron dose was too low to compensate the reduced iron 
levels, or ii) that the time between iron administration (on the day of tumor diagnosis) and 
sampling plasma and tissues was too long. As described above, hematocrit and hemoglobin 
values were not restored (Fig. 18A, B), but plasma iron concentration increased slightly from 
219.5 µg/dl in saline treated to 278 µg/dl (p=0.0286) in iron treated mice (Fig. 18C). However, 
unsaturated and total iron binding capacity also slightly increased from 153.4 µg/dl in saline to 
369.3 µg/dl in iron treated mice (p=0.0122) or from 372.9 µg/dl to 719.4 µg/dl (p=0.0012), 
respectively (Fig. 18D, E). Neither transferrin saturation (Fig. 18F) nor tissue iron 
concentration in liver, spleen and tumors differed between saline and iron treated mice (Fig. 
18G, H, I), suggesting that reduced tissue iron levels could not be restored by iron 
supplementation. Additionally, the incapability to increase hemoglobin levels despite the 
slightly elevated plasma iron levels suggest that supplemented iron was either not available or 
sufficient for erythropoiesis or that iron availability was not rate limiting during erythropoiesis 
in tumor-bearing mice. 
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Fig. 17: Tumor progression, hematology and iron parameters in tumor-bearing Trp53floxWapCre mice after a single 
administration of 13.28 mg/kg of ferric carboxymaltose.  
Shown is (A) Kaplan-Meier survival curve, (B) hematocrit, (C) hemoglobin, (D) spleen weight normalized to the body weight, 
(E) liver weight normalized to the body weight, (F) plasma iron concentration, (G) unsaturated iron binding capacity, (H) total 
iron binding capacity, (I) transferrin saturation, (J) iron concentration in liver, (K) iron concentration in spleen and (L) iron 
concentration in tumor of tumor-bearing Trp53floxWapCre mice receiving an intravenous single injection of 13,28 mg/kg ferric 
carboxymaltose (Ferinject®) (Iron, purple boxes and lines) or saline (NaCl, blue boxes and lines) the day of the tumor 
diagnosis. Mice were euthanized when tumor volume reached maximal permitted size and parameters measured post mortem. 
Black dotted line indicates the median of untreated tumor free mice and red dotted line indicates the median of tumor-bearing 
Trp53floxWapCre mice when tumor volume reached maximal permitted size. Data are shown as (panel A) Kaplan-Meier 
Survival curve (n=10) and (panel B-L) as box plot with min to max whiskers. An Unpaired Student’s t-test was performed for 
panels B-L (n=5-10). 
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Fig. 18: Hematology and iron parameters in tumor-bearing Trp53floxWapCre mice 15 days after a single intravenous 
injection of 20 mg/kg ferric carboxymaltose.  
Shown is (A) hematocrit, (B) hemoglobin, (C) plasma iron concentration, (D) unsaturated iron binding capacity, (E) total iron 
binding capacity, (F) transferrin saturation, (G) iron concentration in liver, (H) iron concentration in spleen and (I) iron 
concentration in tumors of tumor-bearing Trp53floxWapCre mice receiving a single intravenous injection of 20 mg/kg ferric 
carboxymaltose (Ferinject®) (Iron, purple boxes) or saline (NaCl, blue boxes) the day of the tumor diagnosis. Mice were 
euthanized 15 days after iron injection and parameters measured post mortem. Black dotted line indicated the median of 
untreated tumor free mice and red dotted line indicates the median of tumor-bearing Trp53floxWapCre mice when tumor volume 
reached maximal permitted size. Data are shown as box plot with min to max whiskers. An Unpaired Student`s t-test was 
performed (n=6-11); *p<0.05, **<0.01 
 
 
5.8 Iron treatment acutely stimulates erythropoiesis in spleen but not in 
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To analyze if acute iron supplementation might stimulate erythropoiesis, tumor free and tumor-
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tumor-bearing mice (Fig. 19A, B). While the proportion of Ter119+ (late erythroid precursors) 
and CD45/GR1+ (leukocyte precursors) cells in bone marrow did not change in iron treated 
mice, the proportion of Ter119 + in spleen was increased from 41.58 to 53.83% (p=0.0089) and 
the proportion of CD45/GR1+ cells was decreased from 68.03 to 57.05% (p=0.0299) (Fig. 19C, 
D). No effect of the iron treatment was observed in the proportion of the different stages of the 
erythroid precursor’s maturation in the bone marrow nor in the spleen (Fig. 19E-I). These 
results might suggest that ferric carboxymaltose treatment could acutely impact on the stress 
erythropoiesis occurring in the spleen, boosting the production of erythroid cells.  
 
 
Fig 19: Flow cytometry analyses of late erythroid precursors in the bone marrow and spleen of tumor-bearing 
Trp53floxWapCre mice treated 48h before euthanasia with a single i.v. injection of ferric carboxymaltose 
Shown is (A) total cellular number in bone marrow; (B)  total cell number in spleen; (C) percentage of ter119 positive cells in 
bone marrow and spleen (D) percentage of CD45, GR1 positive cells in bone marrow and spleen; (E) percentage of 
erythroblasts; (F) percentage of basophilic erythroblasts; (G) percentage of polychromatic erythroblasts; (H) percentage of 
orthochromatic erythroblasts and reticulocytes and (I) mature erythrocytes in bone marrow and spleen of tumor-bearing mice 
treated with a single i.v. injection of ferric carboxymaltose 48h before tissue sampling (TB iron, garnet boxes) and untreated 
tumor-bearing mice (TB untr, red boxes). Data are shown as box plot with min to max whiskers. An Unpaired Student`s t-test 
was performed (n=4); *p<0.05; **p<0.01. 
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5.9 Impaired bone marrow erythropoiesis in tumor-bearing 
Trp53floxWapCre mice cannot be compensated by activated stress 
erythropoiesis in the spleen 
To analyze erythropoiesis in Trp53floxWapCre tumor-bearing mice we morphologically 
assessed bone marrow smears and quantified the differential cellular count in tumor-bearing 
and tumor free mice. Hematologic precursor cells of tumor-bearing mice were morphologically 
not different from tumor free mice and also no signs of iron deficiency were observed. 
However, the bone marrow smears revealed that the proportion of mature (Fig. 20A) and 
immature erythroid precursors (Fig. 20B) decreased from 40.83% and 1.25% in tumor free 
mice to 17.100% (p=0.0142)  and 0.525% (p=0.0238)  in tumor-bearing mice. In contrast, the 
proportion of late (Fig. 20C) and early myeloid precursor cells (Fig. 20D) increased from 41.18 
to 70.08%(p=0.0076), and from 1.65 to 4.15% (p=0.002) in tumor-bearing mice. Lymphoid 
precursors (Fig. 20F) decreased from 12.35 to 6.025% (p=0.0341) in the tumor-bearing mice, 
and no changes between tumor free and tumor-bearing mice in the proportion of macrophages, 
plasma cells, basophils and eosinophils precursors was observed (Fig. 20G-I). Histological 
analyses of H&E stained bone marrow sections (Fig. 20J, K) showed that cell density did not 
differe between tumor free and tumor-bearing mice (Fig. 20L). However, the H&E bone 
marrow sections visually confirmed the increased number of myeloid precursors and the 
reduced number of erythroid precursors. 
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Fig. 20: Differential cellular count in bone marrow smears and bone marrow histology of tumor-bearing 
Trp53floxWapCre mice 
Shown is the percentage of (A) mature and (B) immature erythroid precursors, (C) mature and (D) immature myeloid 
precursors, (E) monocyte precursors, (F) lymphocytes precursors, (G) plasma cells precursors, (H) basophils precursors and 
(I) eosinophils precursors in bone marrow smears obtained of femurs of age-matched tumor free (TF, white boxes) and tumor-
bearing Trp53floxWapCre mice after reaching maximal permitted tumor size (end stage (ES), red boxes). Panel J and K show 
representative images of H&E stained bone marrow sections of tumor free (J) and tumor-bearing (K) Trp53floxWapCre mice 
after reaching maximal permitted tumor size. Panel (L) shows the cellularity, quantified with Visopharm software, of age-
matched tumor free (TF, white boxes) and tumor-bearing Trp53floxWapCre mice after reaching maximal permitted tumor size 
(end stage (ES), red boxes). Data are shown as box plot with min to max whiskers. An Unpaired Student`s t-test was performed 
(n=4-6); *p<0.05; **p<0.01.  
 
 
To investigate erythropoiesis in bone marrow and spleen of Trp53floxWapCre mice in more 
detail, we used flow cytometry analysis to analyze both, the early and the late stages of the 
erythropoiesis. 
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To analyze the late erythroid precursors at different stages of their maturation, from 
proerytroblast to mature erythrocyte, we isolated bone marrow and spleen cells, labeled them 
with fluorescent CD45, GR-1, Ter119, CD44 antibodies and analyzed them by flow cytometry 
(Fig. 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 21: Flow cytometric analysis of late erythroid maturation in bone marrow and spleen in tumor-bearing 
Trp53floxWapCre mice 
Shown are representative images of the gated plots and the gating strategy used for the erythroid maturation assessment in bone 
marrow of tumor-free mice (A), bone marrow of tumor-bearing mice at end stage (B), spleen of tumor-free control mice (C) 
and spleen of tumor-bearing mice at end stage (D). The gates on the lower plots indicates the different stages of the late 
erythroid maturation: proerythroblasts (I), basophilic erythroblasts (II), polychromatic erythroblasts (III), orthochromatic 
erythroblasts and reticulocytes (IV) and mature erythrocytes (V). 
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The total cell number in bone marrow did not differ between tumor free and tumor-bearing 
Trp53floxWapCre mice (Fig. 22A), confirming the histological bone marrow analyses (Fig. 
20L). The proportion of Ter119 positive erythroid precursors decreased from 45.8% in tumor 
free mice to 23.01% in tumor-bearing mice (p=0.0126) (Fig. 22B) but the proportion of CD45 
and GR-1 positive granulocytes increased from 72.95% in tumor free mice to 89.53% in tumor-
bearing mice (p=0.0183) (Fig. 22C). In contrast to the unchanged cellularity, the reduced 
erythropoiesis and the increased production of granulocytic precursors in bone marrow, the 
spleen cellularity increased in tumor-bearing mice from 2.369x108 to 7.2x108 total cell number 
(p=0.0018) (Fig. 22D), that caused splenomegaly – the enlargement of the spleen (Fig. 9A).  
Additionally, the proportion of erythroid and granulocytic precursors in the spleen, did not 
differ between tumor-bearing and tumor free control mice (Fig. 22E, F). 
 
 
Fig 22: Flow cytometry analysis of late erythroid precursors and granulocyte precursors from bone marrow and 
spleen of tumor-bearing Trp53floxWapCre mice 
Shown is (A) total cellular number, (B) percentage of ter119 positive erythroid precursor cells and the percentage of (C) CD45 
and GR1 positive granulocytes precursor cells in bone marrow as well as (D) the total cellular number, (E) percentage of ter119 
positive erythroid precursor cells and the percentage of (F) CD45 and GR1 positive granulocytes precursor cells in spleen  of 
tumor free (TF, white boxes) and tumor-bearing mice after they reached maximal permitted tumor size (end stage, ES, red 
boxes). Data are shown as box plot with min to max whiskers. An unpaired student`s t-test was performed (n=4); *p<0.05; 
**p<0.01. 
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observed the opposite in the spleen: although we observed no difference in the total amount of 
total late erythroid progenitors between the spleens of tumor-bearing and tumor free mice (Fig. 
22E), the relative proportion of all the stages from proerythroblast to orthochromatic red blood 
cells and reticulocytes increased and the mature red blood cell fraction decreased in tumor-
bearing mice. In detail, proerythroblasts increased from 0.7575 to 3.05% (p=0.0289) (Fig. 
23A), basophilic erythroblasts increased from 4.49 to 10.95% (p=0.0029) (Fig. 23B), 
polychromatic erythroblasts increased from 6.9 to 15.5% (p=0.0084) (Fig. 23C) and 
orthochromatic erythroblasts as well as reticulocytes increased from 15.2 to 25.5% (p=0.0096) 
(Fig. 23D). In contrast, the proportion of mature red blood cells decreased from 68.7 to 40.33% 
(p=0.0022) in the spleen of tumor-bearing mice (Fig. 23E). In conclusion, these results indicate 
that late erythropoiesis is not impaired in bone marrow but a reduced number of erythroid 
precursors occurs. In contrast, late erythropoiesis is boosted in the spleen. 
 
 
 
Fig.23: Flow cytometry analyses of different maturation stages of late erythroid precursors in the bone marrow and 
spleen of tumor-bearing Trp53floxWapCre mice 
Percentage of the different stages of the late erythroid maturation analyzed by flow cytometry: (A) proerythroblasts; (B) 
basophilic erythroblasts; (C) polychromatic erythroblasts; (D) orthochromatic erythroblasts and reticulocytes and (E) mature 
erythrocytes in bone marrow and spleen of tumor free (TF, white boxes) and tumor-bearing mice after they reached maximal 
permitted tumor size (end stage, ES, red boxes). Data are shown as box plot with min to max whiskers. An Unpaired Student`s 
t-test was performed (n=4); *p<0.05; **p<0.01. 
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As a reduction of the proportion of the late erythroid precursors was found in bone marrow, the 
earliest stages of erythropoiesis in this organ were analyzed144 from hematopoietic stem cells 
(HSC) to colony forming units erythrocyte (CFUe ). Bone marrow cells were stained with 
different fluorescently labeled antibodies:  LIN-cocktail, CKit, SCA-1, CD105, CD150, CD48, 
CD41, CD16_CD32 and analyzed by flow cytometry. 
Neither the proportion of hematopoietic stem cells (HSC) nor the downstream multipotent 
progenitor (MPP) differed in tumor-bearing mice (Fig. 24A, B). The percentage of pre-
granulocyte-monocyte lineage cells (PreGM) was increased from 0.797 to 1.32% (p=0.0232) 
in tumor-bearing mice (Fig. 24C) whereas the bipotent pre-megakaryocyte-erythrocyte 
progenitors (Pre MgE) decreased from 0.25 to 0.156% (p=0.0561) (Fig. 24D). No change was 
observed in the erythroid committed restricted progenitors (Pre-CFUe) or in the megakaryocyte 
progenitors (MkP) (Fig. 24E, G), but a reduction on the colony forming units erythrocyte 
(CFUe) from 0.76 to 0.244% (p=0.0039) was observed in bone marrow of tumor-bearing mice 
at end stage (Fig. 24F).  
These results suggest that early erythropoiesis is impaired in bone marrow, and that 
hematopoietic precursors in tumor-bearing mice seem to be more committed towards a 
granulocytic fate in detriment of the erythropoietic cell lineage, driving to a reduced number of 
CFUe and therefore less late erythroid progenitors. 
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Fig. 24: Flow cytometry analyses of different maturation stages of early hematopoietic precursors in the bone marrow 
of tumor-bearing Trp53floxWapCre mice 
Percentage of the different early hematopoietic precursors analyzed by flow cytometry: (A) hematopoietic stem cells (HSC), 
(B) multipotent progenitor (MPP), (C) pre-granulocyte-monocyte lineage cells (PreGM), (D) pre-megakaryocyte-erythrocyte 
progenitors (Pre MgE), (E) pre-colony forming units erythrocyte (CFUe), (F) megakaryocyte progenitors, (G) colony forming 
units erythrocyte (CFUe)  in bone marrow of tumor free (TF, white boxes) and tumor-bearing mice after they reached maximal 
permitted tumor size (end stage, ES, red boxes). Data are shown as box plot with min to max whiskers. An Unpaired Student`s 
t-test was performed (n=4); *p<0.05; **p<0.01. 
  
 
5.10 Hematopoiesis in spleen and bone marrow of Trp53floxWapCre 
mice is differently regulated 
As we observed that erythropoiesis was impaired in bone marrow but not in the spleen, we 
analyzed the mRNA expression in spleen and bone marrow of some proteins related with the 
regulation of the erythropoiesis:  stem cell factor (SCF) and suppressor of cytokine signaling 3 
(SOCS-3) (Fig. 25). Interestingly, we observed that its expression in tumor-bearing animals is 
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altered in bone marrow but not in spleen. The expression of SCF was reduced 4.3-fold 
(p=0.0015) and SOCS-3 was increased 2.41-fold (p=0.0225). 
 
Fig. 25: Bone marrow and spleen mRNA expression of genes related with erythropoiesis in tumor-bearing 
Trp53floxWapCre mice. 
Shown are (A) stem cell factor (SCF) and (B) suppressor of cytokine signaling 3 (SOCS-3) relative mRNA expression 
normalized to b-actin in bone marrow and spleen on of tumor free mice (TF, white boxes) and tumor-bearing at end stage (ES, 
red boxes). Data are shown as box plot with min to max whiskers and an Unpaired Student`s t-test was performed (n=4-6). 
*p<0.05; **p<0.01. 
 
 
As an increase on the myeloid cells proportion was observed, we analyzed granulocyte colony-
stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
expression in tumor tissue.  These cytokines promote the differentiation of hematopoietic 
precursors towards a myelocytic fate. We detected mRNA expression for G-CSF (average CT 
value = 25.8) and for GM-CSF (average CT value = 29.7) in tumor tissue while in the healthy 
mammary tissue mRNA expression was not detected. 
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6. Discussion 
AC impairs the quality of life of cancer patients and might have a deleterious effect on cancer 
disease progression, by promoting the tumor growth and reducing the efficacy of the 
antitumoral agents.18,14 Anemia is also the most common comorbidity among cancer patients 
but despite its high prevalence and critical clinical impact on cancer, it is still nowadays 
underrecognized and undertreated, mainly due to the fact that its pathogenesis is multifactorial 
and the lack of safe and effective therapies.79 To develop or improve treatment strategies, 
preclinical studies of AC are required to recapitulate human pathogenesis. However, only few 
animal models are available125,127,128,145  and, until today, no spontaneous tumor developing 
animal model exists that recapitulates all stages of cancer disease including immunoediting and 
tumor incidence. Thus, we characterized AC in Trp53floxWapCre mice with spontaneous tumor 
development and treated anemic mice with iron supplementation. 
Our results showed that Trp53floxWapCre mice display multifactorial epo-resistant cancer 
related anemia with a prominent inflammation, hypoferremia and inhibition of the medullar 
erythropoiesis. A single intravenous iron injection of ferric carboxymaltose was not effective 
to mitigate anemia in our model because hematopoiesis is altered at the level of early 
hematopoietic precursor cells and not at late stages of progenitors that are already committed 
to the erythroid fate. Thus, Trp53floxWapCre mice mimic the pathology of impaired 
erythropoiesis (especially cytokine-dependent inhibition of erythropoiesis) in AC of human 
patients. 
 
6.1 Trp53floxWapCre mice develop Epo-resistant anemia.  
Trp53floxWapCre mice developed AC during tumor progression in the absence of chemo- or 
radiotherapy. We observed that hemoglobin and hematocrit values were reduced already early 
after tumor onset and continuously declined throughout tumor progression. Cancer associated 
anemia is multifactorial and especially liver and kidney pathologies are very frequent 
comorbidities that can contribute to anemia. However, we found little evidence for a hepatic 
and no evidence for a renal pathology: in the liver, we observed neither morphologic nor 
pathologic or inflammatory changes except a slightly increased cell proliferation. We assume 
that hepatocyte replication (hyperplasia) in anemic tumor-bearing Trp53floxWapCre mice might 
be a consequence of a tumor-induced hepatic synthesis of inflammatory proteins, such of acute 
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phase proteins.146 Epo mRNA levels in the kidney as well as Epo plasma levels were slightly 
increased in anemic tumor-bearing mice suggesting that i) kidney was able to produce Epo and 
ii) mice tried – at least partially – to restore normal blood values by increasing Epo expression. 
In fact, one of the main causes of AC is the reduced renal Epo synthesis.24 Low Epo expression 
levels might be either caused by a kidney malfunction147 or might be the consequence of 
proinflammatory cytokines that inhibit Epo production in the kidney.59,60 Anyway, both 
pathologies result in an inadequate erythropoietic response, which cannot compensate the 
anemia.23 If the slightly elevated Epo levels of 1109 pg/ml in anemic Trp53floxWapCre were 
too low to mitigate anemia in our mouse model is not clear because Epo levels in anemic mice 
strongly depend on mouse strain and the type of anemia.148,126,128   
Epo treatment did not prevent anemia in our anemic tumor model. Because AC is most 
frequently treated with Epo in human patients,78 we did so with our mice. The use of high (1000 
U/kg) Epo dosages did not induce adverse events; neither increased tumor progression nor 
increased mortality, which is an important finding in the light of ongoing debate about ESA 
safety.112 The safety has been questioned within the last decades because several independent 
studies reported on increased mortality among cancer patients due to a higher prevalence of 
thromboembolic events96,97,99,101 or increased tumor growth in some cancer types of cancer.21,110 
Whether or not cancer patients show increased tumor progression after Epo treatment might 
depend on EpoR expression levels in cancer cells and it might be possible that EpoR expression 
levels in Trp53floxWapCre mice are too low to impact on cancer growth. Besides tumor growth, 
Epo treatment in anemic tumor-bearing mice did also not restore the levels of red blood cells. 
To confirm that the Epo non-responsiveness resulted from tumor development and progression 
and not from inactive Epo, we also treated tumor-free Trp53floxWapCre mice with Epo. Because 
tumor free mice responded with increased red blood cells production after Epo administration 
(data not shown), we concluded that only tumor-bearing anemic Trp53floxWapCre mice were 
non-responsive to Epo. Such a non-responsiveness to the ESA treatment also occurs in 35-45% 
of human cancer patients83 and is either caused by  proinflammatory cytokines that inhibit Epo 
signaling149 or by a reduced iron availability for erythropoiesis.150,151  
In our model, mean corpuscular volume (MCV) increased and due to the fact that the mean 
corpuscular hemoglobin (MCH) was not modified, the resulting MCHC value decreased most 
likely due to the increased erythrocyte size (macrocytosis) only.152 The non-regenerative 
macrocytic anemia that we found in anemic tumor-bearing Trp53floxWapCre mice suggests that 
anemia might be caused by an impairment of erythropoiesis. Additionally, it could be also 
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possible that other factors like some nutritional deficiencies such as vitamin-B12 or folate 
deficiency might be also involved.153,154 
Thus, we concluded that tumor-bearing Trp53floxWapCre mice display Epo resistant anemia, 
even when mice were treated with 1000 U/kg of Epo. The medullar erythroid precursors 
response to Epo is impaired in our anemic Trp53floxWapCre mammary cancer mouse model. 
 
6.2 Anemic tumor-bearing Trp53floxWapCre mice show severe 
inflammation and immune response  
Immune system is strongly stimulated in tumor-bearing Trp53floxWapCre mice with a marked 
increase of leukocyte numbers in peripheral blood, especially neutrophils and monocytes as of 
as extensive presence of suppurative inflammation in the tumor tissue. Proinflammatory 
cytokines are the main responsible factors in AC, and IL-6 has a capital role in the AC 
pathogenesis in murine models155 but also in humans.156 It might contribute to the anemia by 
several mechanisms such as decreasing plasma iron availably by promoting iron storage inside 
the cells and reducing intestinal iron absorption,23 or impairing the Epo production in kidney 
and EpoR function in the erythroid precursors.25 Additionally, IL-6 is also involved in some 
metabolic and nutritional disorders as weight loss and cachexia.76 We found increased IL-6 
expression and plasma levels in our tumor-bearing mice suggesting that IL-6 might contribute 
to the anemia onset in our model. In addition, we also observed higher IL-1b mRNA expression 
in tumor tissue than in healthy mammary tissue. IL-1b might impair erythropoiesis by inhibiting 
Epo production and suppressing proliferation and differentiation of erythroid cells.23 
Furthermore, it might also contribute to the hypoferremia by promoting iron storage inside 
macrophages.23 TNFa can suppress erythropoiesis by suppressing autophagy in erythroid 
progenitors, but we observed lower mRNA levels in tumor tissue than in healthy mammary 
tissue. It is important to note that in cancer patients cytokines are not consistently increased in 
plasma157 due to the fact that many cytokines act at paracrine level in different tissues.2 Even 
though, measuring cytokines in plasma might give an indication about which cytokines 
contribute to the anemia pathogenesis in our model and it will be measured in our lab. To 
determine how much the T-cells are involved in the pathogenesis of AC, we transplanted tumors 
of Trp53floxWapCre mice to immunocompromised T-cell negative Foxn1nu mice. 3 out of 5 
animals were prematurely euthanized because of tumor ulceration.  However, we observed that 
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the tumors in these immunocompromised mice slightly decreased hemoglobin, hematocrit and 
serum iron. These data indicate, that T-cells – at least in our model – might not contribute to 
the anemic phenotype, although they have been shown to play an important role in anemia.23  
However, an experiment with a larger number of mice is required to test this assumption. 
We conclude that immune system is strongly activated in tumor-bearing Trp53floxWapCre mice. 
The immune response in tumor-bearing animals is basically characterized by increased levels 
of neutrophils and macrophages which contribute to the production of cytokines like IL-6 and 
IL-1b with likely participate to the anemia onset in our model. 
 
6.3 Hypoferremia in anemic tumor-bearing Trp53floxWapCre  
Reduced iron availability for erythropoiesis as a result of proinflammatory cytokines action, 
specially IL-6, 158 is one of the main etiologic factors in AC.159 Plasma and tissue iron 
concentration were reduced in anemic tumor-bearing Trp53floxWapCre mice, however it has to 
be noted that in liver and spleen total amount of iron stored was higher because the size and 
weight of both organs was increased in tumor-bearing mice. Additionally, also kidney and bone 
marrow showed decreased tissue iron, suggesting an iron-imbalance in tumor-bearing mice.  
We did not observe any special pattern of iron accumulation in tumor tissue, indicating that 
tumor cells or inflammatory cells present on the tumor environment are not entrapping iron. 
Iron deficiency was further suggested by low levels of plasma ferritin, which is an indicator for 
low iron levels in tissue,160 although inflammation usually even increases plasma ferritin.161  
The main mechanism how inflammation-induced IL-6 causes iron deficiency is the 
upregulation of hepcidin,32 that represents the major hormone controlling iron homeostasis.162 
Interestingly, our anemic mice had high levels of IL-6 and low levels of hepcidin, which 
contradicts most animal studies on anemia of inflammation.148 Because we observed no peak 
in hepcidin expression but a progressing decrease from early to late stages of tumor 
development, we concluded that hypoferremia in our model might be caused by hepcidin-
independent mechanisms163 such as hypoferremia due to the induction of Toll-like receptors 2 
and 6.41 However, as hepcidin induction occurs very acutely after the inflammatory insult148,139 
but inflammation in our model is chronic, it might be possible that at the time we analyzed 
hepcidin expression, hepcidin production was already suppressed because low plasma iron 
levels, hypoxia and increased erythropoiesis,164 that might have overwritten the stimulatory 
effect of IL-6. It should be also noted that the iron content in commercial rodent diets is very 
   
 
66 
high (250 mg/kg in our particular diet) and amply exceed iron requirements of mice.165 This 
might cause sustained high hepcidin levels blunting the hepcidin peak that we would expect to 
see as consequence of inflammation.32 However, even after feeding mice with an iron sufficient 
(50 mg/kg iron) diet, hepcidin expression did not increase after tumor onset but decreased, 
indicating that dietary excess of iron is not the cause of the suppression of the expected but 
undetectable hepcidin peak. Bone morphogenic protein-6 (BMP-6) acts as a sensor of iron 
stores and induces hepcidin expression when iron tissue levels are high.33 We observed reduced 
BMP-6 expression in our anemic tumor-bearing mice, suggesting that the progressively 
reducing iron concentration in tissue might contribute to the reduced hepcidin production. 
Hepcidin gene expression is suppressed by erythroferrone (Erfe), which is synthetized by 
erythroid precursors in the bone marrow in response to increased Epo plasma levels.166 In fact, 
we also observed increased Erfe mRNA expression in the bone marrow (but not in the spleen) 
of anemic tumor mice, suggesting that Erfe might contribute to the low hepcidin values. 
Surprisingly, tumor free Trp53floxWapCre mice had higher iron concentration in spleen and 
liver than mice of previous studies, 167,168,169 with the exception of one study were C57BL/6 
also showed elevated iron tissue concentration.139 Trp53floxWapCre mice are on a clean, genetic 
FVB mouse strain background. We compared FVB wild type mice and tumor free 
Trp53floxWapCre mice to verify that the elevated iron levels were not a result of the genetic 
modification in our model. (Fig. S7). Interestingly, wild type FVB mice have equally high 
tissue iron levels than Trp53floxWapCre, but they are 6-8-fold higher than in C58BL/6. Despite 
the high iron content, no iron-induced cytotoxicity was observed. Additionally, our 
Trp53floxWapCre and wildtype FVB mice were around 30 weeks but C57Bl/6 mice only 16 
weeks and ageing causes iron accumulation in tissues. However, age alone is not able to explain 
the difference in the tissue iron concentration between FVB and C57BL/6 mice. We concluded 
that mice on FVB genetic background have an altered iron metabolism that leads to higher iron 
levels and more iron accumulation, which potentially affects hepcidin homeostasis.  
To further characterize hypoferremia in Trp53floxWapCre mice, we analyzed the expression of 
additional genes involved in iron metabolism in the liver. Liver mRNA levels of ferroportin 
(Fpn), the unique known iron exporter, did not change. However, ferroportin is 
posttranscriptionally and posttranslationally modified,170 and mRNA expression levels might 
not reflect the ferroportin protein amount in the cell membranes. The liver mRNA expression 
of heavy ferritin chain (Fth1) decreased in anemic tumor-bearing mice. Ferritin is the main iron 
storage protein and its expression is regulated at different levels by plasma and labile cellular 
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iron concentration as well as inflammation.171 The reduced ferritin plasma levels confirmed the 
reduced mRNA expression in the liver and it is well described that they are reduced when tissue 
iron concentration decrease.160 In contrast, transferrin (Trf)  mRNA expression in liver increases 
in anemic tumor-bearing mice. Transferrin is the main iron transporter in plasma and its 
expression is mainly regulated by inflammatory cytokines,172 and iron levels.173 Although 
transferrin is frequently reported to be down regulated during inflammation,146 it was increased 
at both liver mRNA and plasma protein level in our anemic tumor-bearing mice. The induction 
was indirectly measured by estimating the plasma total iron binding capacity (TIBC), that was 
increased during anemia potentially because decreased serum iron levels were overwriting the 
inflammation-induced suppression of gene expression.173  
In addition to the gene expression in the liver, we analyzed gene expression also in the bone 
marrow of anemic tumor mice. Transferrin receptor 1 (TfR1) mRNA but not transferrin 
receptor-2 (TfR2) mRNA was increased in erythroid cells of bone marrow and spleen. TfR1 
takes up transferrin-bound iron174 and its expression is induced by increased heme levels and 
EpoR downstream signaling.175 This suggests that the erythropoietic cells might try to 
maximize the iron uptake for erythropoiesis. 
We concluded that reduced circulating iron levels in our model was due to the entrapment of 
iron inside spleen and liver. Despite iron concentration is decreased in both organs, the total 
amount of iron stored increases due to the increasing size of both organs throughout the disease. 
Whether this iron entrapment is attributed to hepcidin dependent or independent mechanism 
could not be clearly answered but our data suggest that hepcidin played a minor role in our 
model. However, we did not analyze iron absorption from the diet, which could also be blocked 
in tumor-bearing mice and therefore account for the anemia.176 Additionally, the increased iron 
demand for the aforementioned extramedullary erythropoiesis in the spleen might cause the 
reduced iron plasma levels because iron is required for erythropoiesis.176 Thus, hypoferremia 
in anemic tumor-bearing Trp53floxWapCre mice might be multifactorial. 
 
6.4 Iron supplementation does not mitigate AC in Trp53floxWapCre 
mice  
Trp53floxWapCre develop hypoferremia during the tumor progression and we analyzed if by 
supplementing with iron the anemia could be mitigated in tumor-bearing mice. We 
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intravenously injected anemic tumor-bearing mice with ferric carboxymaltose, that is proven 
to be safe and effective in humans and mice to treat several kind of anemias and replenish iron 
stores.177,178 A single  i.v. injection of 13.28 mg/kg of ferric carboxymaltose directly after tumor 
onset did not increase hemoglobin or hematocrit. Additionally, no increase of iron levels in 
serum or in organs was observed. However, the iron injection did also not increase  tumor 
progression, which is currently a matter of debate if iron supplementation in anemic cancer 
patients promotes tumor growth or induces adverse events.122 To exclude the possibility that i) 
we used an insufficient dosage of the iron or  ii) supplemented iron was used up when tissues 
were harvested, we injected mice with a higher iron dose (20 mg/kg) on the day of tumor onset 
and harvested all tissues 15 days after the treatment. We observed a small increase in plasma 
iron levels but neither hematocrit nor hemoglobin levels increased. Although we cannot exclude 
that a different application strategy might restore normal blood values, our data suggest that 
iron deficiency was not the major reason for AC in our mouse model. To verify this conclusion, 
we injected iron intravenously into anemic tumor mice and analyzed medullar and splenic 
hematopoiesis 48 h post injection. A slightly increased proportion of late erythroid precursors 
in the spleen suggests that stress erythropoiesis is taking place and can be even boosted by the 
supplemented iron. However, iron supplementation has no effect on medullar hematopoiesis. 
This was further supported by the analyses of bone marrow smears that showed no 
morphological modifications which could suggest iron restricted erythropoiesis.179 
Additionally we did not observe microcytic and hypochromic circulating RBC, that are 
frequently observed during anemia caused by iron deficiency.180 Finally, considering the 
aforementioned high baseline levels of iron in FVB mice, further supports our conclusion that 
iron is not the limiting factor in our model. 
In conclusion, hypoferremia in our model seems to play a secondary role on the AC in our 
mouse model and therefore iron supplementation was not able to mitigate the anemia. 
 
6.5 Impaired medullary hematopoiesis in Trp53floxWapCre mice is 
partially compensated by induced stress erythropoiesis in the 
spleen 
Because iron was not the limiting factor that causes AC in our model, we further characterized 
erythropoiesis in anemic tumor-bearing Trp53floxWapCre mice. In the study of the bone marrow 
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smears, we observed that erythroid progenitors were decreased and the proportion of myeloid 
precursors increased in anemic tumor mice. Because the cellularity of the bone marrow did not 
change, these results suggest that erythropoiesis is inhibited in bone marrow whereas 
myelopoiesis is boosted. This fact correlates with other studies of anemia of 
inflamation.181,139,182 Despite the difference in the proportion, the precursor morphology of any 
of the erythropoietic lineages was not changed.   
As the late stages of the medullar erythroid maturation are reported to be impaired in mice with 
anemia of chronic inflamation139 we studied if the blockade of the late erythropoiesis could 
contribute to the anemia in our model. The proportion of Ter119+ cells, i.e. late erythroid 
precursors, was reduced in bone marrow whereas the proportion of CD45/GR1+, i.e. leukocyte 
progenitors, was increased. The relative proportion of the different stages of late erythroid 
maturation, i.e. from proerythroblasts to mature blood cells, in bone marrow did not differ 
between tumor free and tumor-bearing mice, suggesting that late medullar erythropoiesis is not 
blocked in tumor-bearing Trp53floxWapCre mice (Fig. 26). In contrast to the bone marrow the 
spleen responded differently: We observed an increased cellularity and a prominent 
splenomegaly together with no changes in the proportion of late erythroid precursors (Ter119+) 
or leukocyte precursors (CD45/GR1+) (Fig. 26), indicating that both, myelopoiesis as well as 
erythropoiesis are increased in the spleen to a similar extent. However, the relative cell 
proportion within the erythroid linage was increased at all stages of erythroid maturation from 
proerythroblasts to reticulocytes but not at the mature red blood cell stage (Fig. 26). These data 
suggest that anemic tumor mice responded with splenic stress hematopoiesis, which is a fact 
frequently observed in murines when hematopoiesis is accelerated under pathologic 
conditions,183,184 and it has been also reported in other mouse models of AC.185,128   
These results suggest that in bone marrow late erythropoiesis is not impaired but a reduced 
number of late erythroid precursors is present, whereas in the spleen the late erythropoiesis is 
boosted due to stress erythropoiesis. 
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Fig. 26. Representation of the erythropoiesis in bone marrow and spleen of Trp53floxWapCre mice 
Shown are Ter119+(red) and Ter119- (white) cells as well as the five stages (I: proerythroblasts, II: basophilic erythroblasts, 
III: polychromatic erythroblasts, IV: orthochromatic erythroblasts and reticulocytes and V: mature RBC) of late erythroid 
maturation in (A) bone marrow of tumor free mice, (B) bone marrow of tumor-bearing mice as well as (C) spleen of tumor free 
mice and (D) spleen of tumor-bearing mice. The scheme visualizes the that the ratio between Ter119 positive and negative 
cells changes in the bone marrow but not in the spleen of anemic tumor-bearing mice. In contrast, the proportion of the five 
erythrocyte maturation stages does not change in in the bone marrow but in the spleen of anemic tumor-bearing mice. 
 
 
In order to investigate why the number of late erythroid precursors in bone marrow was 
reduced, we analyzed the early stages of the erythropoiesis. The frequency of early 
hematopoietic precursors, namely hematopoietic stem cells (HSC) or in the multipotent 
progenitors (MPP) did not differ between tumor free and anemic tumor-bearing mice, 
suggesting that the stem cell compartment was not impaired (Fig. 27). The increased proportion 
of pre-granulocyte-monocyte lineage cells (pre-GM) and the decreased proportion of pre-
megakaryocyte-erythrocyte progenitors (Pre MgE) (Fig. 27) suggest that hematopoietic cells 
are more committed to the generation of granulocytic cells at expenses of the erythropoietic 
precursors production. The reduced proportion of colony forming units erythrocyte (CFUe) 
(Fig. 27), which are hematopoietic precursors restricted to the red blood cell production, further 
supported these findings. 
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Fig. 27. Schematic representations of alteration in the hematopoietic tree in anemic tumor mice. 
Shown is the hematopoietic tree with symbols indicating the changes in tumor-bearing anemic mice: no change visualized by 
equal symbol, increased proportion visualized by red ascending arrow, decreased proportion visualized by red descending 
arrow or a decreasing trend visualized by red, dotted descending arrow. Proportion of both pre-megakaryocyte-erythrocyte (Pre 
MgE) and colony forming units erythrocyte (CFU) are decreased, proportion of pre-granulocyte-monocyte progenitors (Pre-
GM), which give rise to granulocytes are increased. Hematopoietic stem cells (HSC), multipotent progenitor (MPP), pre-colony 
forming units erythrocyte (Pre-CFUe), megakaryocyte progenitors (Mkp).  
 
In summary, we found evidence that the reduced number of bone marrow born erythroid cells 
is a consequence of a shift during early hematopoiesis, where the fate of precursors shifts from 
erythroid to myeloid (granulocytes) fate. The decreased erythrocyte production in bone marrow 
of anemic Trp53floxWapCre mice is partially compensated by a prominent extramedullary 
hematopoiesis in the spleen, that, however, is not sufficient to fully compensate the impaired 
RBC production. In contrast, myelopoiesis boosted in both hematopoietic organs, causing the 
increase of the granulocytic cells output. 
 
6.6 Secretion of cytokines by the tumor might stimulate the 
myelopoiesis in bone marrow and prevent erythropoiesis in 
Trp53floxWapCre mice 
Induced granulocytosis in anemic Trp53floxWapCre mice is also frequently observed in humans 
patients with different types of cancer186,187,188,189 (including breast carcinomas190,182) and 
associates with a poor prognosis.191 Similarly also tumor mouse models respond with induced 
2B). Together, these observations suggest a long-term surge
in erythroid progenitor populations at the expense of
myeloid progenitors, starting with CMP (Figure 2C).
To understand this differential response between HSCs
and MPPs, and the reduction in downstream myeloid pro-
genitors, we studied cell-cycle progression in the hemato-
poietic stem and progenitor cell (HSPC) compartment. To
this end, we found that a significantly higher number of
Tg6 HSCs progressed through the cell cycle compared
withWT HSCs. In contrast, Tg6MPPs were more quiescent
compared with their WT counterparts (Figures S2A and
2D). As the latter displays an apparent discrepancy with
the increase in total MPP numbers, we decided to define
the telomere lengths in MPPs from Tg6 and WT mice, as
these are a measure of the number of times a (stem) cell
has divided over time (Chiu et al., 1996). Our analyses
revealed significantly shorter telomeres in Tg6 MPPs than
i W MPPs, which suggests longer overall survival and
subdued differentiation (less downstream progenitors) of
Tg6 MPPs, despite reduced instant proliferation. Further-
more, we also examined MPPs in 4-week-old mice and
found a clear trend toward lower numbers of Tg6 MPPs
compared with WT littermates (Figure S2B). Conversely,
we found no increased cycling of Tg6 MPPs in these
4-week-old mice (Figure S2C), although MPP cell numbers
in 6-week-old animals were no longer different (Figure S2B)
and further reverted in adult mice (Figure 2B). This further
supports the notion that, already at an early stage, Tg6
MPPs showmore preference to self-renew than to differen-
tiate in comparison with WT MPPs.
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Figure 2. Tg6 Mice Display an Increased HSC/MPP Compartment
(A) Gating strategy and representative fluorescence-activated c l so ting (FACS) plots of hematopoietic stem progenitor cell populations.
(B) Proportion and total HSC and MPP numbers fromWT d Tg6 mice (n = 5–7), one of mor than five epr sen tive experiments is shown.
(C) The overall effect of chronic and continuous high EPO exposur on the classical representation of the hematopoietic tree taken from
data presented in Figures 1, 2, and S1.
(D) Bar graphs representing the fraction of HSCs and MPPs in the quiescent G0 phase of the cell cycle (left) and progressing through the cell
cycle (non-G0, right), (n = 15–17), from four independent experiments. Gating strategy as shown in Figure S2A.
(E) Relative telomere length of isolated MPPs from both genotypes (n = 5–6). Values are mean ± SEM. *p < 0.05.
See also Figure S2.
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myeloid response.192,193,145,194 This myeloid response produce the increase of tumor-associated 
myeloid cells (TAMC), including myeloid-derived suppressor cells (MDSCs), neutrophils, and 
macrophages which promote cancer progression195,196 through different mechanisms: modulate 
adaptive immune responses against tumors197,198, enhance cancer cell stemness,199 and support 
angiogenesis, invasion, and metastasis.200,197,201  
The concentration of some cytokines produced by the tumor or inflammatory cells correlates 
with the severity of the anemia in chronic disease states202,203 as well as with the induced 
myeloid expansion. For example, in murine 4T1 breast tumor-bearing mice, it has been shown 
that some colony-stimulating factors (G-CSF, GM-CSF, M-CSF) produced by the tumor, 
caused a leukemoid reaction, i.e. a very severe stimulation of the leukocyte production, in bone 
marrow and spleen and thus blocking medullar erythropoiesis.128,182 We analyzed the gene 
expression of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-
colony stimulating factor (G-CSF) and indeed we found mRNA of both factors was detected in 
tumor tissue of anemic tumor-bearing Trp53floxWapCre mice but not in heathy mammary gland 
tissue. G-CSF is the primary extracellular regulator of the granulopoiesis,204 and GM-CSF has 
been reported to synergistically act with G-CSF to enhance the granulopoyesis.205 Additionally, 
it has been shown that G-CSF can mobilize HSC from the bone marrow which accumulate in 
the spleen, serving as the precursors for the extramedullary hematopoiesis.206  
The expression of the stem cell factor (SCF), which is an essential regulator of the 
erythropoiesis which acts coordinately with Epo to maintain and stimulate erythropoiesis,207 
was reduced in the bone marrow, whereas in the spleen was not modified. Its expression is 
downregulated by proinflammatory cytokines like IL-6 and IL-1b. 
Some cytokines produce its inhibitory effect on the erythropoiesis through the suppressor of 
cytokine signaling-3 (SOCS-3),25 which mediates inhibition of Epo-R signaling62 and also SCF 
expression.25 SOCS-3 mRNA expression was also higher in bone marrow of anemic tumor-
bearing mice than in tumor free mice. In contrast, SOCS-3 mRNA was not increased in the 
spleen, another possible explanation why spleen was able increase production of RBC and bone 
marrow not.  
Therefore, we assume that cytokines and not iron deficiency causes the inhibition of the 
medullar erythropoiesis due to the inhibition of Epo downstream signaling, the suppression of 
SCF expression and the shift on the hematopoietic progenitors towards a granulocytic fate (Fig. 
28). 
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Fig. 28: Pathogenesis of AC in Trp53floxWapCre mice 
Tumor cells and immune cells of the tumor microenvironment secrete cytokines which inhibit erythropoiesis through the 
inhibition of Epo signaling and the downregulation of stem cell factor (SCF) expression. Additionally, tumor and inflammatory 
cells produce granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-
CSF) which promote stress hematopoiesis in the spleen, which in one hand partially palliates the anemia but also contribute to 
the production of tumor associated myeloid cells (TAMC). Additionally, G-CSF and GM-CSF act on the bone marrow 
promoting the shift of the hematopoiesis towards the production of TAMC at expenses of the erythropoiesis. TAMC contribute 
to the cancer progression and to the disease perpetuation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Veterinary Physiology
Page 42
Tumor and immune cells
Proinflammatory cytokinesG-CSF and GM-CSF
Spleen Stress 
Hematopoiesis
Deviation hematopoiesis 
towards myeloid fate
Anemia
TAMC
Erythrocytes
Epo signaling SCF
Medullar erythropoiesis
Figure 28 
   
 
74 
7. Conclusion and outlook 
In conclusion, we showed that tumor-bearing Trp53floxWapCre mice develop anemia, which 
could neither be corrected by Epo treatment nor by iron supplementation as monotherapy 
(although mice developed hypoferremia). Hypoferremia might be caused by cytokines like IL-
6 or IL-1b but because iron might not be limiting erythropoiesis, hypoferremia has only a 
secondary role in AC in our mouse model. Thus, we conclude that inflammation and cytokines 
suppress erythropoiesis independently of iron in tumor-bearing Trp53floxWapCre mice. We 
found evidence for two potential pathways of cytokine mediated suppression of medullar 
erythropoiesis: i) proinflammatory cytokines such IL-6 and IL-1b seem to inhibit EpoR 
downstream signaling and SCF expression, e.g. by increasing the mRNA expression of EpoR 
signaling suppressor SOCS-3. ii) Proinflammatory cytokines such G-CSF and GM-CSF seem 
to change the differentiation of hematopoietic progenitors by shifting cell differentiation from 
erythroid linage to a granulocyte fate. Both pathways can explain why anemic tumor-bearing 
mice do not respond to Epo treatment, even when very high dosages were used. 
To our knowledge, the Trp53floxWapCre mouse model is the first one that mimics Epo non-
responsiveness similar to human cancer patients and thus, could be a good candidate to analyze 
this particular type of AC with regard to cellular and molecular differences within the erythroid 
linage and potential anti-inflammatory treatment options. 
Future experiments may involve the complete the characterization of this mouse model of AC. 
To have a more accurate picture of the inflammatory status of our tumor-bearing mice, the 
plasmatic concentration of some cytokines that might be involved in the medullar 
erythropoiesis inhibition need to be analyzed. Additionally, the lifespan of the circulating 
erythrocytes in our tumor mice should be measured, since it has been reported that inflammation 
might increase erythrocyte turnover,148 and therefore, it may be a contributing factor to the AC 
pathogenesis in our model. Finally, recent studies about the role of splenic stress erythropoiesis 
on the shift of hematopoietic progenitors fate towards a myeloid fate have been published128,195  
and our mouse model might be a good candidate to study the crosstalk between spleen and bone 
marrow in AC. 
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9. Supplemental 
 
 
Figure S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. Tumor tissue of tumor-bearing Trp53floxWapCre 
Shown is a representative H&E stained tissue section of tumor tissue of a Trp53floxWapCre when the mouse reached 
experimental termination criteria by maximum permitted tumor size (end stage). Upper part of the picture: mammary carcinoma 
cells with diffuse neutrophilic inflammation (black arrows). Lower part (black rectangle): extensive necrotic area with degraded 
neutrophilic infiltrated (black arrows). Scale bar 250 µm.  
 
 
 
 
Figure S2 
 
 
 
 
 
 
 
 
 
 
Fig. S2. Ki67 immunostaining on liver of Trp53floxWapCre 
Shown are representative ki-67 immunostained tissue sections of liver of (A) tumor free and (B) tumor-bearing at end stage 
Trp53floxWapCre mice. Panel C shows the percentage of Ki-67+ cells in liver of tumor free (TF, white boxes) and tumor-
bearing mice at end stage (ES, red boxes). End stage was considered when the mouse reached experimental termination criteria 
by maximum permitted tumor size. An Unpaired Student’s t-test (panel C) was performed. (n=4). Scale bar 500 µm.  
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Fig. S3: Tumor progression, hematology and iron parameters in tumor-bearing Trp53floxWapCre mice fed with an iron 
sufficient diet (50 mg/kg) from 18 weeks of age  
Shown is (A) Kaplan-Meier survival curve, (B) hematocrit, (C) hemoglobin, (D) plasma iron concentration, (E) unsaturated 
iron binding capacity, (F) total iron binding capacity (G) transferrin saturation, (H) relative mRNA hepcidin-1 expression, (I) 
iron concentration in liver, (J) iron concentration in spleen and (K) iron concentration in tumor of free mice (TF, white boxes) 
and tumor-bearing (red boxes) Trp53floxWapCre mice at different stages of tumor progression: immediately after tumor 
diagnosis (0d), 7 days after tumor diagnosis (7d) and at end stage (ES, when maximal permitted tumor size was reached). 
Animals were fed with an iron sufficient diet (50 mg/kg). Black dotted line indicates the median of tumor free mice fed with a 
standard diet (250 mg/kg iron) and red dotted line indicates the median of tumor-bearing Trp53floxWapCre mice at end stage 
fed with the standard diet (250 mg/kg iron). Data are shown as (panel A) Kaplan-Meier Survival curve (n=3-7) and (panel B-
K) as box plot with min to max whiskers. One-way ANOVA with Dunnett’s Multiple Comparison post hoc test (panel B-H), 
a Mann Whitney test (panel I, K) or an Unpaired Student’s t-test (panel J) was performed. (n=5-11). ****p<0.000, *p<0.05, 
***p<0.001, **p<0.01.  
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Figure S4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4. Iron accumulation and distribution in spleen, liver, bone marrow, kidney and tumor of Trp53floxWapCre mice 
fed with an iron sufficient diet (50 mg/kg) from 18 weeks of age. 
Tissue sections were stained with Perls' DAB-enhanced to stain (A, B) spleen, (C, D) liver, (E, F) bone marrow, (G, H) kidney 
and (I) tumor tissue. Shown are representative images of tumor free mice (left panels) and tumor-bearing mice at end stage, 
i.e. when they reached maximal permitted tumor size (right panels) Trp53floxWapCre mice fed with an iron sufficient diet (50 
mg/kg Fe) from 18 weeks of age. Scale bar 100 or 250 µm. 
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Fig. S5.  Correlation between different parameters related to anemia in cancer in Trp53floxWapCre mice fed with an 
iron sufficient diet (50 mg/kg) from 18 weeks of age. 
Shown is the linear correlation analysis of liver weight normalized to the body weight (y-axis) vs. (A) tumor weight, (B) iron 
concentration in serum, (C) transferrin saturation, and (D) total binding capacity. Hemoglobin (E), spleen weight (F) and iron 
concentration in serum (G) versus tumor weight. Hemoglobin (H), spleen weight (I), liver weight normalized to body weight 
(J) and iron concentration in serum (K) vs. the survival (days) of tumor-bearing Trp53floxWapCre mice fed with an iron 
sufficient diet (50 mg/kg) from 18 weeks of age at different stages of the disease. Data shown as individual mouse data with 
regression lines. Linear regression analyses were performed. R2 is the coefficient of determination and p the p-value. (n=5-19) 
 
0 1000 2000 3000 4000
0
20
40
60
80
100
Tumor weight vs. liver weight
Total tumor weight (mg)
liv
er
 (m
g)
/b
od
yw
ei
gh
t (
g) R2=0.1866
p=0.0648
Total iron binding capacity vs. liver weight
TIBC [µg/dl]
0 200 400 600 800
0
20
40
60
80
100 R2=4912
p=0.0012
Li
ve
r (
m
g)
/b
od
yw
ei
gh
t
0 1000 2000 3000 4000
0
100
200
300
Total tumor weight (mg)
SF
B
C
 [µ
g/
dl
]
R2=0.4831
p=0.004
Tumor weight vs. 
iron concentration in serum
0 100 200 300
0
20
40
60
80
100
SFBC [µg/dl] 
R2=0.2349
p=0.0354
Iron concentration in serum vs. 
liver weight
Li
ve
r (
m
g)
/b
od
yw
ei
gh
t
0 1000 2000 3000 4000
80
100
120
140
Total tumor weight (mg)
H
b 
[g
/d
l]
R2=0.4469
p=0.0018
Tumor weight vs. hemoglobin
0 10 20 30 40 50
80
90
100
110
120
130
Survival [Days]
H
b 
[g
/d
l]
R2=0.001827
p=0.9275
Survival of tumor mice vs. 
hemoglobin
Transferrin Satturation [%]
Li
ve
r (
m
g)
/b
od
yw
ei
gh
t
0 50 100 150
0
20
40
60
80
100
R2=0.3816
p=0.0063
Transferrin saturation vs. liver weight
0 1000 2000 3000 4000
0
5
10
15
20
Tumor weight vs. spleen weight
Total tumor weight (mg)
Sp
le
en
 (m
g)
/B
od
yw
ei
gh
t (
g) R2=0.5769
p=0.0002
0 10 20 30 40 50
0
5
10
15
20
Survival [Days]
Sp
le
en
 (m
g)
/b
od
yw
ei
gh
t (
g)
R2=0.04956
p=0.6313
Survival of tumor mice vs. 
spleen weight
0 10 20 30 40 50
0
20
40
60
80
100
Survival [Days]
R2=0.0383
p=0.6741
Survival of tumor mice vs.
 liver weight
Li
ve
r (
m
g)
/b
od
yw
ei
gh
t
0 10 20 30 40 50
100
120
140
160
180
200
Survival [Days]
SF
B
C
 [µ
m
ol
/l]
R2=0.05154
p=0.7134
Survival of tumor mice vs. 
iron concentration in serum
Figure S5 
A
I
E F
C
K
H
B
J
G
D
   
 
88 
  
 
Fig. S6: Hematology, organ weight, tumor onset and survival of tumor-bearing Trp53floxWapCre mice fed with an iron 
sufficient diet (50 mg/kg) from birth. 
Shown is (A) hematocrit, (B) hemoglobin, (C) spleen weight and (D) liver weight normalized to the body weight. (E) Kaplan-
Meier survival curve of the tumor onset and (F) Kaplan-Meier survival curve of the tumor-bearing mice reaching end stage 
(ES, when maximal permitted tumor size was reached).  Animals were fed with a standard diet containing 250 mg/kg iron [ES 
(SD), red boxes] or with an iron sufficient diet (50 mg/kg) [ES (IS), purple boxes]. Data are shown as (panel A-D) box plot 
with min to max whiskers and (panel E, F) Kaplan-Meier Survival curve. An Unpaired Student’s t-test (A, C) or a Mann 
Whitney test (B, D) was performed (n=8-37). *p<0.05. 
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Fig. S7: Comparation of tissue iron in Trp53floxWapCre mice with FVB wildtype and BL6 wildtype mice  
Shown is (A) iron concentration in liver, (B) total iron content in liver (C) iron concentration in spleen (D) and total iron 
content in spleen (E) of tumor-bearing Trp53floxWapCre mice at end stage, i.e. reaching maximal permitted tumor size (ES, 
red boxes), tumor-free Trp53floxWapCre mice (TF, white boxes), FVB wild type mice (FVB, grey boxes) and C57BL/6 wild 
type mice (BL6).  Data are shown as box plot with min to max whiskers. One-way ANOVA with a Dunn’s Multiple 
Comparison post hoc test was performed (n=2-9). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.  
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